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ABSTRACT 
 
The Roles of Nicotinic and Muscarinic Cholinergic Receptors in 
Risky and Impulsive Decision Making. (December 2010) 
Ian Alfredo Mendez, B.A.; M.A., California State University, San Marcos 
Co-Chairs of Advisory Committee: Dr. Antonio Cepeda-Benito 
     Dr. Barry Setlow 
 
 Psychopathological conditions in which decision making is impaired are 
common and include schizophrenia, attention deficit hyperactivity disorder, and 
addiction, among others. This dissertation aimed to investigate the role of cholinergic 
signaling in risky and impulsive decision making. Rats were trained in either a 
“probability discounting” task in which they chose between small guaranteed and large 
probabilistically delivered food rewards (a measure of risky decision making), or a 
“delay discounting” task in which they chose between small immediate and large 
delayed food rewards (a measure of impulsive decision making). Rats were also divided 
into high and low “risk-taking” or “impulsive” groups on the basis of their performance 
in the tasks.  
Experiments 1 and 2 examined the effects of cholinergic drugs on performance in 
the probability and delay discounting task, respectively. In Experiment 1, acute 
administration of the acetylcholinesterase inhibitor donepezil decreased choice of the 
large risky reward in “risk-taking” rats. Acute administration of nicotine increased 
choice of the large risky reward in both groups, whereas administration of the nicotinic 
 iv
receptor antagonist mecamylamine decreased choice of the large risky reward in “risk-
taking” rats. In Experiment 2, nicotine increased choice of the large delayed reward and 
mecamylamine shifted impulsive choice in a non-specific manner in “impulsive” rats. 
The muscarinic receptor agonist oxotremorine decreased choice of the large delayed 
reward in “non-impulsive” rats and increased choice in “impulsive” rats, while treatment 
with the muscarinic receptor antagonist atropine increased impulsive choice in all rats.  
In Experiment 3, another group of rats was used to examine correlations between 
baseline performance in both discounting tasks and nicotinic receptor density levels in 
several brain regions. Impulsive choice was positively correlated with α4β2 receptor 
levels in ventral hippocampus and nucleus accumbens shell, and α7 receptor levels in the 
basolateral amygdala, such that greater impulsivity was associated with higher receptor 
levels.  Additionally, risky choice was negatively correlated with α4β2 receptor levels in 
nucleus accumbens shell, such that greater risk was associated with lower receptor 
levels. These experiments suggest that cholinergic receptors are involved in cost-benefit 
decision making and that they may prove a useful target for treatment of 
psychopathological conditions in which decision-making deficits are present. 
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INTRODUCTION AND LITERATURE REVIEW 
 
Cost-benefit decision making is an executive function characterized by the ability 
to make choices among reward options for which the outcomes differ in both cost and 
magnitude. Optimal cost-benefit decision making yields actions that return maximum 
rewards with minimal costs. Variations in the costs associated with a reward, however, 
may cause that reward to become more or less advantageous. To decide if selection of a 
reward is more or less advantageous, proper integration and evaluation of costs and 
rewards, as well as appropriate conflict resolution, are required. Encoding stimulus 
values, integration and consideration of gains and losses, and resolution of response 
conflict (all processes necessary for cost-benefit decision-making) are associated with 
frontal cortical areas (Beer et al. 2006; Critchley and Rolls 1996; Elliott et al. 2003; 
Wittfoth et al. 2009). The ventral tegmental area and the nucleus accumbens of the 
mesolimbic system have also been associated with processes necessary for cost-benefit 
decision making, including processing of reward and punishment, encoding of stimulus 
salience and reward value, and when working in concert with cortical areas, prediction 
of future rewards and punishments (O'Doherty 2004; Tom et al. 2007; Weller et al. 
2007). The amygdala has also been shown to play a role in reward prediction; however, 
this role may be limited to predicting reward gain, and not reward loss (Tom et al. 2007; 
Weller et al. 2007).  
Poor cost-benefit decision making results in impulsive and/or risky behavior,  
____________ 
This dissertation follows the style of Psychopharmacology. 
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which can negatively impact the finances, social relationships, and health of the 
individual. Psychopathological conditions in which decision making is impaired are 
common and include schizophrenia, Alzheimer’s disease, attention deficit hyperactivity 
disorder, Parkinson’s disease, and addiction (Clark and Robbins 2002; Coyle et al. 1983; 
Euteneuer et al. 2009; Kalivas and Volkow 2005; Thompson et al. 2007; Weiler et al. 
2009; Yip et al. 2009). Several neurotransmitter systems have been implicated in cost-
benefit decision making, including dopamine, serotonin, and norepinephrine (Dallery 
and Locey 2005; Hoffman et al. 2006; Mobini et al. 2000; Winstanley et al. 2006). The 
cholinergic system has been linked with either the etiology and/or treatment of 
psychopathological conditions associated with altered cost-benefit decision making; 
however, in contrast with other neurotransmitter systems, little is known about its direct 
roles in cost-benefit decision making.  
Acetylcholine is found in neurons projecting from the nucleus basalis 
(particularly in the nucleus basalis of Meynert) to neocortical areas, from the adjacent 
medial septum and diagonal band of Broca to the hippocampus, from the 
pedunculopontine nucleus in the brainstem to the ventral tegmental area, and in 
interneurons within the striatum (Butcher 1994; Squire 1986). Cholinergic neurons in the 
pedunculopontine nucleus that project to the midbrain activate both nicotinic and 
muscarinic acetylcholine receptors (AChRs) in the ventral tegmental area. (Good and 
Lupica 2009). Both nicotinic and muscarinic AChRs are found on dopamine neurons 
that project from the ventral tegmental area to the nucleus accumbens, and when 
activated, are suggested to underlie increases in reward salience and incentive 
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motivation for primary and secondary reinforcers (Picciotto et al. 2008; Zhang and 
Sulzer 2004). Nicotinic and muscarinic AChRs within the prefrontal cortex are 
implicated in executive function, and their activation has been suggested to improve 
cognitive performance (Cutuli et al. 2008; Furey et al. 2000; Furey et al. 2008; Ricciardi 
et al. 2009). Current research now suggests a role for both nicotinic and muscarinic 
AChRs in some of the underlying component psychological processes necessary for 
cost-benefit decision making, including executive functions within the PFC and 
incentive motivation within the mesolimbic system (Cutuli et al. 2008; Furey et al. 2008; 
Picciotto et al. 2008; Ricciardi et al. 2009). However, as mentioned above, there is very 
little direct evidence concerning the role of acetylcholine in cost-benefit decision 
making. 
Research using cost-benefit decision making tasks in human smokers has begun 
to suggest a possible relationship between changes in nicotine levels and impulsive and 
risky decision making. Impulsive decision making is often assessed using delay 
discounting tasks, in which subjects are required to choose between a small immediate 
reward and a large reward with delays to its delivery (Evenden and Ryan 1996a). An 
increased preference for the immediate, less advantageous reward is suggestive of 
enhanced impulsivity. Research using delay discounting tasks has shown that long-term 
nicotine smokers will select the small immediate reward over the larger delayed reward 
more often than control subjects (Bickel et al. 1999; Field et al. 2006). The probability 
discounting task can assess risky decision making by requiring subjects to choose 
between a guaranteed small reward and a larger reward with varying probabilities of 
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delivery (Mobini et al. 2002). The probability discounting task has also been used to 
investigate risky decision making in nicotine smokers; however, these studies have 
produced mixed findings, reporting that smoking may increase, decrease, or have no 
effect on the preference for large, risky rewards over smaller guaranteed rewards 
(Mitchell 1999; Reynolds et al. 2004; Yu and Dayan 2005).  
Although these correlational studies have shown an association between nicotine 
use and changes in cost-benefit decision making, it is not clear whether nicotine use 
(through smoking) causes changes in cost-benefit decision making or whether abnormal 
cost-benefit decision making is a predisposing factor for nicotine use. Because of the 
lack of understanding regarding the causality of this relationship, intrigue remains about 
whether or not changes in the activation of cholinergic receptors can affect cost-benefit 
decision making. To date only one study has investigated the causality of the 
relationship between changes in cholinergic activity and cost-benefit decision making. In 
this study, (Dallery and Locey 2005), the effects of several doses of nicotine (0.03, 0.1, 
0.3, and 1.0 mg/kg, s.c.) on delay discounting were assessed in rats. Acute nicotine dose-
dependently increased impulsive choice (increased choice of the small, immediate 
reward), while chronic exposure (once a day for 65 days) to each of the doses tested 
increased impulsive choice equally across all doses used. Furthermore, increases in 
impulsive choice were reported up to 30 days after discontinuation of nicotine treatment.  
Decision making deficits observed in psychopathological conditions may be 
driven by alterations in cholinergic systems (Decker et al. 1997; Dellu et al. 1991; Diaz 
del Guante et al. 1991; Potter et al. 2006); therefore, the cholinergic system may provide 
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a target for pharmacological treatment of psychopathological conditions in which altered 
decision making is prominent. Clinical trials investigating the effects of cholinergic 
supplementation on cognitive deficits associated with numerous psychopathological 
conditions are currently underway (Kadir et al. 2008; Lemay et al. 2004; Winhusen et al. 
2005). However, to better understand how alterations in cholinergic systems may 
contribute to decision making deficits, it will be necessary to define the role of the 
cholinergic system in normal decision making. The overall goal of this dissertation was 
to determine the role that cholinergic receptors play in cost-benefit decision making 
Two sets of experiments used a behavioral pharmacology approach to investigate 
the role of nicotinic and muscarinic AChRs in cost-benefit decision making. Experiment 
1 aimed to determine if experimental modulation of the cholinergic system could affect 
decision making for outcomes that involve possible risk of reward loss. To address this 
question, the effects of both nicotinic and muscarinic non-selective receptor agonists 
(nicotine and oxotremorine, respectively) and antagonists (mecamylamine and atropine, 
respectively), as well as an acetylcholinesterase inhibitor (donepezil), on performance in 
the probability discounting task were assessed. Experiment 2 aimed to determine if 
experimental modulation of nicotinic and muscarinic AChRs could affect decision 
making for outcomes involving delays to reward delivery. To address this question, 
identical methods as those used in Experiment 1 were used; however, impulsive decision 
making was assessed by testing animals in the delay-discounting task. Experiment 3 
investigated relationships between baseline cost-benefit decision making and intrinsic 
nAChR subtype levels. This was accomplished by using radioligand receptor binding to 
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examine the relationship between baseline performance on both the probability and 
delay discounting tasks and nAChR subtype (α4β2 and α7) levels in brain regions 
implicated in cost-benefit decision making in previous experiments.  
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GENERAL METHODS 
 
Subjects 
The subjects were male Long-Evans rats that weighed 250-275g upon arrival 
(Charles River Laboratories, Wilmington, NC, USA). Experiment 1 utilized 15 rats, 
while Experiment 2 and 3 used separate cohorts of 16 rats each. Rats were housed 
individually in a climate-controlled vivarium (25o C) in the Department of Psychology at 
Texas A&M University. Rats had food and water available ad lib (except as noted 
below). Testing was done during the light cycle of a 12-hour light/dark schedule (lights 
on 0800-2000). Animal testing was conducted according to the “Principles of Laboratory 
Animal Care” (National Academy of Sciences, USA) and met all NIH and institutional 
animal care and use guidelines. Rats were allowed to acclimate to vivarium conditions 
for at least one week before the start of data collection. Prior to testing in the discounting 
and instrumental responding tasks, all animals were food restricted to 85% of their free 
feeding weight. Upon completion of these tasks, rats were returned to an ad lib feeding 
schedule.  
 
Behavioral Apparatus 
Decision making and instrumental responding were assessed in eight identical 
standard rat behavioral test chambers (31 X 25 X 31 cm) with aluminum front and back 
walls, acrylic side walls, and a floor composed of steel rods (0.4 cm diameter, spaced 1.1 
cm apart), and located in sound-attenuating cubicles (Coulbourn Instruments, Allentown, 
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PA, USA). A recessed food delivery trough (4.1 X 3.2 cm) equipped with a photobeam 
to detect head entries was placed in the center of the front wall of the chambers (2.2 cm 
above the floor). For the discounting tasks, a standard retractable response lever was 
placed on each side of the food trough (11 cm above the floor), and they were extended 
and withdrawn as described in the task behavioral protocol. When testing instrumental 
responding in these chambers, only 1 retractable response lever was extended, and the 
side that had the extended lever was counterbalanced across groups. The chambers were 
interfaced with a computer running Graphic State 3.01 software (Coulbourn Instruments) 
to control stimulus deliveries and record data. 
Activity and exploratory measures were collected in eight identical activity 
monitoring chambers (Versamax System, Accuscan Instruments, Columbus, OH, USA). 
Each chamber (40×40×30 cm) contained an array of photobeams raised 0.5 cm above 
the floor to detect movement in the horizontal plane. The activity chambers were 
connected to a computer running Versamap software (Accuscan Instruments) which 
recorded photobeam breaks. 
 
Behavioral Protocols 
Probability Discounting Task 
Test sessions for the probability discounting task were run once a day. Each 
session was 60 minutes long and consisted of five blocks of 18 trials each. Each 40-
second trial began with a 10 second illumination of the food trough and house lights. A 
nose poke into the food trough during this time extinguished the food trough light and 
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triggered extension of either a single lever (forced choice trials) or both levers 
simultaneously (choice trials). Trials on which rats failed to nosepoke during this time 
window were scored as omissions. A press on one lever (either left or right, 
counterbalanced across animals) resulted in a single food pellet (the small reward) being 
delivered immediately following the lever press. A press on the other lever resulted in 
delivery of two food pellets (the large reward). During the first block of trials, the large 
reward was delivered with 100% probability following selection of the large reward 
lever. During each of the four subsequent blocks, the probability of large reward delivery 
was systematically decreased (75, 50, 25, 0%). Each 18 trial block began with eight 
forced choice trials used to expose the rats to the reward probabilities in effect for that 
block (4 for each lever), followed by 10 choice trials. Once either lever was pressed, 
both levers were immediately retracted. Food delivery was accompanied by re-
illumination of both the food trough and house lights, which were extinguished upon 
entry to the food trough to collect the food or after 10 seconds, whichever occurred first.  
To determine baseline responding, animals were run on this task until five 
consecutive sessions of stable responding and a within-session effect of probability 
block were achieved (Cardinal et al. 2000b; Simon et al. 2007; Winstanley et al. 2006). 
Following stable responding, animals were treated every other day with systemic 
administration of one of four doses of a cholinergic drug no more than 30 minutes prior 
to testing, with treatments administered in a counterbalanced order across animals. On 
the days between treatment days animals were run in the task with no pharmacological 
manipulation.  
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Delay Discounting Task 
In the delay discounting task, rats were again given the option between a small 
immediate, guaranteed reward and a large discounted reward. However, in the delay 
discounting task, the large rewards were guaranteed on each trial, but delayed in their 
delivery. Sessions were 60 minutes long and consisted of five blocks of 12 trials each. 
Each 60-second trial began with illumination of the food trough and house lights. In this 
task, a press on one lever (either left or right, counterbalanced across subjects) resulted 
in 1 food pellet delivered immediately, and a press on the other lever resulted in delivery 
of 3 food pellets after a delay. The duration of the delay varied with each block (0s, 4s, 
8s, 16s, 32s) on a schedule that has been shown to produce a robust discounting curve 
(Evenden and Ryan 1996b; Simon et al. 2009; Winstanley et al. 2006). Following stable 
responding, animals were again treated every other day with systemic administration of 
one of four doses of a cholinergic drug no more than 30 minutes prior to testing, with 
treatments administered in a counterbalanced order. On the days between treatment days 
animals were run in the task with no pharmacological manipulation.  
Instrumental Responding Task 
Instrumental responding for single pellet food rewards was first assessed using 
fixed ratio schedules (FR1, 3, 10, 20, 40, one schedule/day). Test sessions in the fixed 
ratio task were 30 minutes in length and occurred once a day. After testing with the fixed 
ratio schedules, instrumental responding was assessed in one session using a progressive 
ratio schedule of reinforcement, on which the number of lever presses required to earn a 
reward increased with each successive reward earned (1, 4, 10, 20, 35, …) (Barr and 
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Phillips 1999; Cetin et al. 2004; Kheramin et al. 2005). These sessions varied in length, 
ending only after an hour with no reward delivery had passed (the breakpoint).  
Open Field Test 
To obtain a baseline measure of exploratory behavior when introduced to a novel 
environment, rats were placed in locomotor activity chambers for a 1 hour test session, 
during which data on horizontal activity and time spent in center region were collected 
to assess locomotor and exploratory behavior, respectively. Locomotor activity was 
tested under red light and white noise conditions. 
 
Radioligand Binding Protocol 
A receptor binding experiment examined nAChR levels in brain regions 
associated with impulsive and risky decision making, including structures within the 
striatum and prefrontal cortex. Sixteen rats were trained and tested in both the 
probability and risk discounting task. Rats were tested in one of the two tasks until 5 
consecutive sessions of stable responding were reached, then switched over to the other 
task again until 5 sessions of stable responding were achieved. Immediately following 
completion of the two discounting tasks, rats were run in the instrumental responding 
task and Open Field Test described above. Rats were then deeply anesthetized with 
inhaled isoflurane and sacrificed for brain harvesting.  
Collected brains were immediately frozen at –30o C in isopentane for 60 seconds, 
and stored at –80o C. Twenty micrometer thick coronal brain sections were taken on a 
cryostat at –18o C from cortical (orbitofrontal, medial prefrontal, infralimbic, prelimbic, 
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cingulate, and agranular insular cortex) and limbic (nucleus accumbens shell and core, 
basolateral amygdala, and ventral and dorsal hippocampus) structures in the forebrain, as 
well as structures within the midbrain (ventral tegmental area,), and mounted onto 
Superfrost-plus microscope slides (VWR, USA). Slides were kept on ice during cutting, 
then desiccated overnight at 4o C and temporarily stored at –80o C. Using receptor 
autoradiography, nAChR subtype levels were identified using 125I radioligands. 
Epibetadine was used to identify α4β2 nAChR subtype, while α-bungarotoxin was used 
to identify the α7 nAChR subtype. Tissue sections were pre-incubated in fresh Tris-HCl 
buffer solution (50 mM Tris-HCl base, 120 mM NaCl, 5 mM KCl, 2.5 mM CaCl2, and 1 
mM MgCl2, adjusted to pH 7.4 with 10 N HCl) for 5 minutes. For total binding, sections 
were incubated at room temperature with predetermined radioligand for a set amount of 
time, within the Tris-HCl buffer. Adjacent sections designated for nonspecific binding 
were processed in the presence of 100 µM of nicotine hydrogen tartrate, which was 
added to pre-incubation and incubation buffers. Sections were incubated at room 
temperature for 60 minutes and washed in ice-cold incubation buffer twice for 5 minutes 
each, followed by ice-cold ddH2O for 30 seconds, dried under constant airflow for 1 
hour at room temperature and exposed to film (Kodak Biomax MR Film) along with 
[125I]-standards of known radioactivity.  
After film exposure for several days (2 days for epibetadine, 3 days for α-
bungarotoxin) the films were developed in D19 Kodak developer for 4 minutes, rinsed in 
water, and fixed in Kodak Rapid Fixer for 5 minutes. The slides were then exposed to 
vapor fixation and stained in Cresyl Violet solution to assist the analysis. Images from 
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autoradiograms were quantitatively analyzed using a PC-based image analysis system 
(InterFocus Imaging Ltd., UK). A calibration curve of radioactivity nCi/mg tissue versus 
optical density was generated using the [125I]-standard for receptor ligand binding.  
 
Statistical Analysis 
Raw data files were exported from Graphic State software and were compiled 
using a custom macro written for Microsoft Excel (Dr. Jonathan Lifshitz, Spinal Cord 
and Brain Injury Research Center, University of Kentucky). Statistical analyses were 
conducted in SPSS 16.0. Response omission and intertrial interval (ITI) activity during 
treatment days were assessed using repeated measures ANOVA. Stable behavior was 
determined using a two-way repeated measures ANOVA (Session x Probability/Delay), 
across 5 consecutive days, and was defined by a main effect of trial block in the absence 
of a main effect or interaction involving day. Primary and post-hoc analyses of the 
probabilistic and delay discounting tasks on drug treatment days were conducted using 
two-way repeated measures ANOVA (Dose X Probability/Delay). Stable behavior was 
also determined for intertreatment days using a two-way repeated measures ANOVA 
(Day x Probability/Delay), across each of the 4 days that followed the treatment days, 
and was defined by the absence of a main effect of day or interaction between day and 
block. Relationships between baseline behavioral performance and receptor binding data 
were determined using two-tailed Pearson’s bi-variate correlations. In all cases, p values 
less than .05 were considered significant.  
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EXPERIMENT 1. ROLE OF NICOTINIC AND MUSCARINIC RECEPTORS  
IN PROBABALISTIC DECISION MAKING 
 
Experiment 1.1. Effects of the Acetylcholinesterase Inhibitor Donepezil on 
Performance in the Probability Discounting Task 
To begin to understand the role cholinergic systems may play in risky behavior, 
the effects of the centrally acting reversible acetylcholinesterase inhibitor donepezil on 
performance in the probability discounting task were assessed. This task characterizes 
the ability of varying food reward probabilities to promote discounting of a large reward, 
and is considered to assess risk-taking behavior (Mobini et al. 2002). Based on the 
general cognitive enhancing effects reported following increases in acetylcholine (Cutuli 
et al. 2008; Furey et al. 2000; Furey et al. 2008; Ricciardi et al. 2009), it was predicted 
that donepezil would improve decision making by decreasing disadvantageous risky 
responding in the probability discounting task.  
Treatment 
Following stable responding in the probability discounting task, animals were 
treated every other day with systemic administration of one of four doses of donepezil 
(0, 0.3, 1.0, 3.0 mg/kg, i.p.) 30 minutes prior to testing in the task. All drugs were 
purchased from Sigma Aldrich, except for donepezil, which was purchased from A&A 
Pharmachem. All drugs were dissolved in 0.9% saline, and administered at a volume of 
1 ml/kg. 
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Results  
No significant effects of donepezil treatment on response omissions were 
observed during test days in the probabilistic discounting task (Table 1). Conversely, a 
significant effect of donepezil treatment on ITI locomotor activity, during test days in 
the probabilistic discounting task, was observed (F(3,42) = 4.74, p < .01, Table 1). Post-
hoc analyses revealed no significant effects when comparing ITI activity following 
treatment with only the low or middle dose of donepezil to that following treatment with 
saline; however, a significant decrease in activity was observed when comparing activity 
following saline treatment to that following treatment with the high dose of donepezil (p 
< .01).  
 
Table 1. Effects of Cholinergic Drugs on Response Omissions and Locomotor Activity 
During Testing in the Probability Discounting Task. 
 Dose 
Donepezil 
Experiment  
1.1 
Nicotine 
Experiment  
1.2 
   Oxotremorine
   Experiment  
1.3 
  Mecamylamine 
Experiment  
1.4 
Atropine 
Experiment  
1.5 
       
 
Mean Percent 
Choice Trials 
Omitted 
 
 
Veh 
Low 
Med 
Hi 
0.3% 
4.4% 
0.0% 
0.7% 
0.3% 
0.1% 
0.0% 
 6.1% * 
0.4% 
 10.8% * 
4.3% 
 24.9% * 
2.0% 
1.2% 
1.6% 
2.1% 
4.5% 
22.4% * 
41.6% * 
49.3% * 
       
Mean ITI 
Locomotor Activity 
(beam breaks)  
 
Veh 
Low 
Med 
Hi 
2068 
1858 
1877 
  1481 * 
2382 
2621 
   2939 * 
1949 
1983 
1499 
  1480 * 
    987 * 
1618 
1463 
1637 
1490 
1395 
1383 
1230 
1319 
       
* = significantly different from Veh 
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Analysis of 5 days of baseline responding prior to testing using a two-way 
repeated measures ANOVA showed no significant main effect of day (F(4,56) = 1.13, p = 
.35) or interaction between day and block (F(16,224)=.89, p = .58), but a significant effect 
of probability (F(4,56) = 171.66, p < .01). This suggests that animals were responding 
stably before treatment began and that they discounted the large reward as a function of 
the probability of its delivery. The effects of all doses of donepezil on the performance 
of rats in the probabilistic decision making task were assessed using a two-factor 
repeated measures ANOVA. A significant main effect of dose (F(3,39) = 2.91, p < .05) 
was observed in our initial analysis, although there was no significant interaction 
between dose and block (F(12,156) = 1.70, p = .07). Post-hoc analysis using two-factor 
ANOVA compared each drug dose with saline control conditions and revealed no 
significant effects, although treatment with the high dose of donepezil caused a near 
significant increase in preference for the large risky reward (p = .08), when compared to 
choice preference following treatment with saline.  
Although there were no significant effects found when comparing each dose 
individually with saline conditions, interesting trends in performance were observed 
following treatment with each dose of donepezil. A small shift in preference toward the 
smaller, safer reward was observed following treatment with either the low or middle 
dose of donepezil; conversely, a moderate shift in preference toward the larger, risky 
reward was observed following treatment with the high dose of donepezil (Figure 1(A)). 
These trends, along with an overall main effect of drug dose, supported additional 
analyses of the data obtained. Baseline performance on the probability discounting task 
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allows for the characterization of the rats’ “natural” propensity for risk-taking. To 
examine how donepezil administration interacted with baseline levels of risk taking, 
animals from this experiment were split into “risk-taking” and “risk-averse” groups 
based on whether they fell above or below the median percentage of choices (averaged 
across blocks) of the large, risky reward during the 5 days of stable responding 
immediately prior to testing with the drug.  
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(B)       (C) 
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Figure 1. Effects of donepezil treatment on responding in the probability discounting task. (A) 
Treatment with donepezil significantly affected performance in the probability discounting task, 
when testing all rats. However, post-hoc analyses revealed no between group differences. (B) 
Treatment with all doses of donepezil significantly shifted the performance of risk-taking rats in the 
probability discounting task. Post-hoc analyses revealed that the middle and high doses of donepezil 
(black triangles, squares, and circles, respectively) significantly shifted preference towards the small 
reward when compared to performance following treatment with saline. (white circles) (C) No 
significant shift in performance was observed in risk-averse rats following treatment with donepezil, 
when compared to performance following treatment with saline. * p < .05. 
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The effects of all doses of donepezil on the performance of risk-taking rats in the 
probabilistic decision making task were assessed using a two-factor repeated measures 
ANOVA. In risk taking rats, a significant main effect of dose (F(3,18) = 3.76, p < .05) and 
a significant interaction between dose and block (F(12,72) = 2.62, p < .01) were observed. 
Individual post-hoc comparisons with a two-factor ANOVA revealed that following 
treatment with the middle and high doses of donepezil prior to testing, risk-taking rats 
significantly shifted their preference towards the smaller, safer reward across the five 
blocks, when compared to their performance after saline treatment (ps < .01). Although 
treatment with the low dose of donepezil caused a similar shift in preference to that seen 
with the higher doses in risk-taking rats, this effect was not quite significant (p = .06). 
Thus, donepezil appeared to decrease risk-taking in rats with high baseline levels of risk-
taking (Figure 1(B)). 
A two-factor repeated measures ANOVA was again used to assess the effects of 
donepezil on the performance of risk-averse rats in the probabilistic decision making 
task. There was no significant main effect of dose (F(3,18) = 2.95, p = .06) or interaction 
between dose and block (F(12,72) = 1.17, p = .32). Risk-averse rats did show a modest 
shift toward preference for the larger risky reward, when comparing choice preference 
following treatment with the highest dose of donepezil to that following treatment with 
saline. Nonetheless, analysis suggests that donepezil does not appear to significantly 
alter risk-taking in rats with low baseline levels of risk-taking (Figure 1(C)).  
The most apparent difference between the risk-taking and risk-averse rats was 
that risk taking rats chose the larger, risky reward much more often during the 4th 
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session block. Selection of the large reward is considered a “risky” decision because 
delivery of the large reward is not guaranteed (except during block 1). Furthermore, 
although selection of the large reward is risky, these choices do not necessarily become 
less advantageous, or “poor” decisions, until the 4th session block (25% probability), 
when choice of the large reward yields less total food delivery across the 10 choice trials 
(5 pellets), than selection of the small guaranteed reward (10 pellets). Because donepezil 
decreased risky decision making in risk-taking rats, these data suggest that increases in 
acetylcholine availability can improve cost-benefit decision making. The observed 
results in risk-taking rats support our prediction that increases in acetylcholine can 
decrease risky decision making, as determined by the probability discounting task. These 
results also suggest that the observed effect may be dependent on differences in baseline 
risk behavior, which in turn, may be dependent on intrinsic differences in cholinergic 
function (the relationship between such intrinsic differences in acetylcholine systems 
and decision making was investigated in Experiment 3). 
 
Experiment 1.2. Effects of the Nicotinic Receptor Agonist Nicotine on Performance 
in the Probability Discounting Task 
Changes in nicotinic acetylcholine receptor (nAChR) function may underlie 
deficits in cost-benefit decision making, which are characteristic of several 
psychopathological conditions including ADHD, Parkinson’s disease, and addiction 
(Clark and Robbins 2002; Coyle et al. 1983; Kalivas and Volkow 2005; Thompson et al. 
2007). The purpose of this experiment was to investigate the effects of acute 
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administration of several doses of the non-selective nAChR agonist nicotine on 
probabilistic decision making. Research has shown increases in cognitive function 
following acute nicotine administration (Cutuli et al. 2008; Furey et al. 2000; Furey et al. 
2008; Ricciardi et al. 2009). However, both acute and chronic nicotine have been shown 
to cause increases in impulsive decision making (Dallery and Locey 2005). Based on the 
observed decrease in risky behavior following treatment with donepezil, it was predicted 
that rats with high baseline levels of risk-taking would shift their preference toward the 
smaller, safer reward following acute treatment with nicotine. 
Treatment 
This experiment used the same design and statistical analysis as Experiment 1.1; 
however, the effects of the nAChR agonist nicotine (0, 0.1, 0.3, 1.0 mg/kg, s.c.) were 
investigated instead. In addition, the large reward consisted of 4 pellets and the 
probability of its delivery was decreased across the 5 blocks at a schedule of 50, 25, 
12.5, and 0 percent. This change was made in an attempt to shift the baseline response 
curve to be more centered in the parametric space. 
Results  
Significant effects of nicotine treatment on response omissions and ITI 
locomotor activity, during test days in the probabilistic discounting task, were observed 
(Table 1). A significant effect of nicotine dose was observed when comparing response 
omissions during treatment days (F(3,42) = 6.83, p < .01). Post-hoc analyses revealed no 
significant effects when comparing response omissions following treatment with only 
the low or middle dose of nicotine to that following treatment with saline, but omissions 
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significantly increased with the high dose of nicotine (p < .05). A significant effect of 
nicotine dose was also observed when comparing ITI locomotor activity during 
treatment days (F(3,30) = 7.16, p < .01). Post-hoc analyses revealed no significant effects 
when comparing ITI activity following treatment with only the low or high dose of 
nicotine to that following treatment with saline; however, results do show that ITI 
activity significantly increased when comparing activity following treatment with the 
middle dose of nicotine to that following treatment with saline (p < .05).  
Analysis of 5 days of baseline responding prior to testing using a two-way 
repeated measures ANOVA showed no significant main effect of day (F(4,56) = 1.40, p = 
.25) or interaction between day and block (F(16,224) = .83, p = .66), but a significant effect 
of probability (F(4,56) = 255.85, p < .01), indicating that animals were responding stably 
before treatment began. The effects of all doses of nicotine on the performance of rats in 
the probabilistic decision making task were assessed using a two-factor repeated 
measures ANOVA. A significant main effect of dose (F(3,36) = 13.04, p < .001) and a 
significant interaction between dose and block (F(12,144) = 4.64, p < .001) were observed. 
Individual post-hoc comparisons with a two-factor ANOVA revealed that treatment with 
the highest dose of nicotine significantly increased preference for the large risky reward 
when compared to saline (p < .01). Post-hoc analyses revealed no significant effects 
when comparing performance on the task following treatment with the low and middle 
dose of nicotine with performance after saline treatment. Thus, nicotine appeared to 
increase risk-taking in rats (Figure 2(A)). 
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As with the donepezil experiment (Experiment 1.1), animals were split into risk-
taking and risk-averse groups based on whether they fell above or below the median 
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Figure 2. Effects of nicotine treatment on responding in the probability discounting task. (A) 
Analysis of treatment with all doses of nicotine showed a significant shift in performance in the 
probability discounting task. Post-hoc analyses revealed that the high dose of nicotine (black 
circles) significantly shifted preference towards the large reward when compared to performance 
following treatment with saline. (white circles). (B) Risk-taking rats treated with all doses of 
nicotine significantly shifted their preference in the probability discounting task. Post-hoc analyses 
revealed that the low dose of nicotine (black triangles) significantly shifted preference towards the 
small, safe reward, while treatment with the high dose of nicotine (black circles) significantly 
shifted preference towards the large, risky reward, when compared to performance following 
treatment with saline. (white circles) (C) Risk-averse rats treated with all doses of nicotine also 
significantly shifted their performance in the probability discounting task. Post-hoc analyses 
revealed that both the middle (black squares) and high dose of nicotine (black circles) resulted in a 
significant increase in preference towards the large, risky reward, when compared to performance 
following treatment with saline. (white circles). * p < .05. 
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percent choice (averaged across blocks) of the large, risky reward during the 5 days of 
stable responding immediately prior to testing. The effects of all doses of nicotine on the 
performance of risk-taking rats in the probabilistic decision making task were assessed 
using a two-factor repeated measures ANOVA. A significant main effect of dose (F(3,18) 
= 5.45, p < .01) and a significant interaction between dose and block (F(12,72) = 1.93, p < 
.05) were observed. Individual post-hoc comparisons using a two-way repeated 
measures ANOVA revealed a significant increase in preference for the large risky 
reward, when comparing performance following treatment with the highest dose of 
nicotine to performance following saline treatment (p < .01), in risk-taking rats. 
Conversely, post-hoc analyses also revealed a significant decrease in preference for the 
large risky reward, when comparing performance on the task following treatment with 
the low dose of nicotine to performance after saline treatment (p < .05). No post-hoc 
effects were observed when comparing performance on the task following treatment 
with the middle dose of nicotine with performance after saline treatment. Thus, nicotine 
appeared to both increase and decrease risk-taking in rats with high baseline levels of 
risk-taking, depending on the dose (Figure 2(B)). 
The effects of all doses of nicotine on the performance of risk-averse rats in the 
probabilistic decision making task were also assessed using a two-factor repeated 
measures ANOVA. A significant main effect of dose (F(3,15) = 12.21, p < .001) and a 
significant interaction between dose and block (F(12,60) = 4.58, p < .001) were observed.  
Individual post-hoc analyses using a two-factor ANOVA resulted in a significant 
increase in preference for the large risky reward (ps < .05), when comparing rats 
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performance following treatment with both the middle and high dose of nicotine to  
performance following saline treatment, in risk-averse rats. Post-hoc analyses revealed 
no significant changes in choice preference when comparing performance following 
treatment with the low dose of nicotine to performance after saline treatment. Thus, 
nicotine appeared to increase risk-taking in rats with low baseline levels of risk-taking 
(Figure 2(C)). 
Findings suggest that nAChRs are involved in probabilistic decision making. The 
results observed in risk-taking rats following treatment with the low dose of nicotine 
support our predictions (based on Experiment 1.1) that increases in nAChR activity 
would decrease risk-taking. Interestingly, treatment with the high dose of nicotine 
caused increases in risky behavior in both risk-taking and risk-averse rats. Together with 
the findings of Dallery and Locey, these data suggest that acute treatment with nicotine 
in rats will cause shifts in choice preference when testing in the probability and delay 
discounting tasks. What remains unclear are the mechanisms through which acute 
treatment with nicotine affects discounting in these tasks. Activation of nAChRs within 
the mesolimbic system has been shown to increase reward salience and reinforcement, as 
well as incentive motivation (Picciotto et al. 2008; Zhang and Sulzer 2004). These 
motivational increases may explain why nicotine treated rats were willing to respond for 
larger amounts of food reward, even when that reward was accompanied by a high risk 
of loss.  
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Experiment 1.3. Effects of the Muscarinic Receptor Agonist Oxotremorine on 
Performance in the Probability Discounting Task 
Although muscarinic acetylcholine receptors (mAChRs) have been implicated in 
various forms of executive function, whether or not mAChR are involved in cost-benefit 
decision making is unknown (Friedman 2004; Gasbarri et al. 1997; Levin et al. 1997a). 
The purpose of this experiment was to investigate the effects of acute administration of 
several doses of the non-selective mAChR agonist oxotremorine on probabilistic 
decision making. Although general muscarinic activation within the prefrontal cortex is 
associated with enhanced cognition (Chen et al. 2004; Chouinard et al. 1995; De Rosa 
and Hasselmo 2000), the effects of mAChR activation within the mesolimbic system on 
cost-benefit decision making are unclear. There is some evidence that the mAChRs 
subtypes M1, M3, M4, and M5 are implicated in the evaluation of rewards; for example, 
activation of the M1 subtype has been shown to increase at the end of a meal, suggesting 
a possible role in signaling hedonic satiation and inhibition of reward seeking and taking 
behaviors (Levey et al. 1995; Pratt and Kelley 2004; Pratt et al. 2007). Based on the 
observed decrease in risky behavior following treatment with donepezil, it was predicted 
that rats with high baseline levels of risk-taking would shift their preference toward the 
smaller, safer reward following acute treatment with oxotremorine. 
Treatment 
This experiment used the same experimental design and statistical analysis as 
Experiment 1.2; however, the effects of the non-selective mAChR agonist oxotremorine 
(0, 0.03, 0.1, 0.3 mg/kg, i.p.) were investigated instead. 
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Results  
Significant effects of oxotremorine on response omissions and ITI locomotor 
activity during test days in the probabilistic discounting task were observed (Table 1). A 
significant effect of oxotremorine dose was observed when comparing response 
omissions during treatment days (F(3,45) = 10.49, p < .01). Post-hoc analyses revealed a 
near significant effect when comparing response omissions following treatment with 
middle dose of oxotremorine to that following treatment with saline (p = .06), and 
response omissions significantly increased following treatment with the low and high 
doses of oxotremorine (p < .05). A significant effect of oxotremorine dose was observed 
when comparing ITI locomotor activity during treatment days (F(3,42) = 5.17, p < .01). 
Post-hoc analyses revealed no significant effects when comparing ITI activity following 
treatment with only the low dose of oxotremorine to that following treatment with saline; 
however, results do show that ITI activity significantly decreased when comparing 
activity following treatment with the either the middle or high dose of oxotremorine to 
that following treatment with saline (ps < .05).  
Analysis of 5 days of baseline responding prior to testing using a two-way 
repeated measures ANOVA showed no significant main effect of day (F(4,52) = .38, p = 
.82) or interaction between day and block (F(16,208) = .92, p = .55), but a significant effect 
of probability (F(4,52) = 12.48, p < .01). This suggests that animals were responding 
stably before treatment began. Treatment with the high dose of oxotremorine greatly 
increased response omissions in the task (8 rats omitting responses in at least 7 of the 10 
choice trials for at least 1 block with the high dose, versus 2 rats with the low and 
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medium dose), resulting in insufficient data for analysis. Thus, data from the high dose 
were eliminated in subsequent analyses. Analysis of data from saline, as well as the low 
and middle doses of oxotremorine, using a two-factor repeated measures ANOVA 
revealed no significant main effect of dose (F(2,22) = .91, p = .42) or interaction between 
dose and block (F(8,88) = 1.58, p = .14). Thus, oxotremorine did not appear to affect risk-
taking when analyzing data from all rats (Figure 3(A)).  
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Figure 3. Effects of oxotremorine treatment on responding in the probability discounting task. (A) 
Treatment with oxotremorine resulted in no significant shifts in performance in the probability 
discounting task, when compared to preference following treatment with saline. Effects of the 
highest doses are not reported due an increase in response omissions. (B) Treatment with 
oxotremorine showed no significant shift in risk-taking rats in performance on the probability 
discounting task, when compared to performance following treatment with saline. (C) Similar to 
risk-taking rats, risk averse rats showed no significant shift in performance following treatment 
with oxotremorine, when comparing to performance following treatment with saline.  
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As in previous experiments, animals were split into risk-taking and risk-averse 
groups based on whether they fell above or below the median percent of choice for the 
large, risky reward, totaled across blocks. The effects of all doses of oxotremorine on the 
performance of risk-taking and risk-averse rats in the probabilistic decision making task 
were assessed using a two-factor repeated measures ANOVA. Similar to the results 
observed when comparing all rats, in risk-taking rats, results indicated no main effect of 
dose (F(2,8) = 1.54, p = .27) or interaction between dose and block (F(8,32) = .90, p = .53), 
on performance in the task. Thus, oxotremorine did not appear to affect risk-taking in 
rats with high baseline levels of risk-taking (Figure 3(B)). Furthermore, no main effect 
of dose (F(2,12) = .75, p = .49) or interaction between dose and block (F(8,48) = 1.13, p = 
.36) on performance was observed in risk-averse rats. Thus, oxotremorine did not appear 
to affect risk-taking in rats with low baseline levels of risk-taking (Figure 3(C)). 
Available data from this experiment did not support our predicted results that activation 
of mAChRs would decrease risky decision making, as assessed by performance in the 
probability discounting task. 
 
Experiment 1.4. Effects of the Nicotinic Receptor Antagonist Mecamylamine on 
Performance in the Probability Discounting Task 
In addition to testing the effects of nicotinic and muscarinic AChR agonists on 
probabilistic discounting, this dissertation project also examined the effects of nicotinic 
and muscarinic AChR antagonists on probabilistic discounting. Experiment 1.4 used 
systemic administration of the non-selective nAChR antagonist mecamylamine, to 
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determine the effects of nAChR blockade on performance in the probability discounting 
task. Based on data from Experiment 1.2, suggesting that increased activation of nAChR 
increases risk-taking behavior when testing all rats, it was predicted that blockade of 
nicotinic cholinergic receptors would decrease risk-taking behavior in all rats. This 
would be evident as a decrease in preference for the large risky reward on the 
probabilistic decision making task following acute treatment with the nAChR antagonist 
mecamylamine. 
Treatment 
This experiment used the same design and statistical analysis as Experiment 1.3; 
however, the effects of the nAChR antagonist mecamylamine (0, 0.5, 1.0, 2.0 mg/kg, 
s.c.), on performance in the probability discounting task, were investigated instead.  
Results 
No significant effects of mecamylamine treatment on response omissions and 
locomotor activity during test days in the probabilistic discounting task were observed 
(Table 1). Analysis of 5 days of baseline responding prior to testing using a two-way 
repeated measures ANOVA showed no significant main effect of day (F(4,56) = 1.29, p = 
.29) or interaction between day and block (F(16,224) = .86, p = .62), but a significant effect 
of probability (F(4,56) = 476, p < .01), indicating that animals were responding stably 
before treatment began. The effects of all doses of mecamylamine on the performance of 
rats in the probabilistic decision making task were assessed using a two-factor repeated 
measures ANOVA. No significant main effect of dose (F(3,36) = 2.02, p = .13) or 
interaction between dose and block (F(12,144) = 1.68, p = .08) were observed. However, 
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rats did show a modest shift toward preference for the larger risky reward, when 
comparing choice preference following treatment with the highest dose of 
mecamylamine to that following treatment with saline (Figure 4(A)).  
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Animals were again split into risk-taking and risk-averse groups based on 
whether they fell above or below the median percent choice (averaged across blocks) of 
Figure 4. Effects of mecamylamine treatment on responding in the probability discounting task. 
(A) Treatment with all doses of mecamylamine resulted in no significant shift in preference for 
reward, when compared to performance following treatment with saline. (B) Treatment with all 
doses of mecamylamine significantly shifted the performance of risk-taking rats in the probability 
discounting task. Post-hoc analyses revealed that the 0.5 dose of mecamylamine (black triangles) 
significantly shifted preference towards the small, safe reward when compared to performance 
following treatment with saline. (white circles) (C) Risk-averse rats did not significantly shift 
their performance in the probability discounting task following treatment with mecamylamine, 
when compared to performance following treatment with saline. * p < .05.
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the large, risky reward, during the 5 days of stable responding immediately prior to 
testing. The effects of all doses of mecamylamine on the performance of risk-taking rats 
in the probabilistic decision making task were assessed using a two-factor repeated 
measures ANOVA. In risk taking rats, no significant main effect of dose (F(3,18) = 2.70, p 
= .08), but a significant between dose and block interaction (F(12,72) = 2.21, p < .05) was 
observed. Individual post-hoc comparisons with a two-factor ANOVA revealed that 
following treatment with the low dose of mecamylamine, risk-taking rats significantly 
shifted their preference towards the smaller, safer reward across the five blocks, when 
compared to their performance after saline treatment (p < .05). Thus, mecamylamine 
appeared to decrease risk-taking in rats with high baseline levels of risk-taking (Figure 
4(B)).  
No main effect of dose (F(3,15) = 2.36, p = .11) or interaction effect (F(12,60) = 
1.35, p = .21) was observed in risk-averse rats, again when comparing all doses of 
mecamylamine. However, rats did show a modest shift toward preference for the larger 
risky reward, when comparing choice preference following treatment with the highest 
dose of mecamylamine to that following treatment with saline (Figure 4(C)).  
The results of this experiment do not support our predictions (based on 
Experiment 1.2) that decreases in nAChR activity cause a decrease in risky-choice in all 
rats. However, treatment with the low dose did cause a significant decrease when 
analyzing data from only risk-taking rats, providing further support that nAChRs are 
involved in probabilistic decision making. These data suggest that rats with high baseline 
levels of risky decision making will show more discounting of large food rewards that 
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are risky following acute treatment with mecamylamine.  Activation of nAChRs in the 
ventral tegmental area has been shown to increase reward salience and reinforcement, as 
well as incentive motivation (Picciotto et al. 2008; Zhang and Sulzer 2004). These 
reported nAChR activity-dependent increases in reward salience and reinforcement may 
explain why blockade of nAChRs decreased motivation for the larger food reward 
options, particularly when accompanied by a high risk of reward loss.  
 
Experiment 1.5. Effects of the Muscarinic Receptor Antagonist Atropine on 
Performance in the Probability Discounting Task 
This experiment used systemic administration of the non-selective mAChR 
antagonist atropine, to determine its effects on performance on the probability 
discounting task. Because high levels of mAChR activation caused problems with 
instrumental performance in the task, and lower levels of activation did not appear to 
affect risk-taking, it was predicted that blockade of mAChR would not strongly affect 
performance in the probabilistic task and that this would be evident in both whole-group 
and split analyses. Blockade of mAChR could also interfere with task performance in a 
non-specific manner. This would be evident as an increase in the number of omitted 
responses, as seen with oxotremorine. 
Treatment 
Experiment 1.5 used the same experimental design and statistical analysis as 
Experiment 1.4 described above. However, the effects of the mAChR antagonist 
atropine (0, 0.3, 1, 3.0 mg/kg, i.p.) were investigated instead.  
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Results 
A significant effect of atropine dose was observed when comparing response 
omissions during treatment days in the probabilistic discounting task (F(3,45) = 17.55, p < 
.01, Table 1). Post-hoc analyses revealed significant effects when comparing response 
omissions following treatment with each individual dose of atropine to that following 
treatment with saline (ps < .01). Similar to results seen with the high dose of nicotine, 
the effect of the low dose of atropine on omissions was primarily carried by a few rats, 
allowing for group data analysis. No significant effect of atropine treatment, on ITI 
locomotor activity, during treatment days in the probabilistic discounting task, was 
observed (Table 1).  
Analysis of 5 days of baseline responding prior to testing using a two-way 
repeated measures ANOVA showed no significant main effect of day (F(4,56) = 2.09, p = 
.10) or interaction between day and block (F(16,224) = 1.34, p = .18), but a significant 
effect of probability (F(4,56) = 311.21, p < .01). This suggests that animals were 
responding stably before treatment began. Treatment with the middle and high dose of 
atropine greatly increased response omissions in the task (following treatment with the 
low dose, 4 rats omitted responses in at least 7 of the 10 choice trials available in a 
block, for at least 1 block, versus 10 and 9 rats with the medium and high dose, 
respectively), resulting in insufficient data for reliable analysis. Thus, data from the 
middle and high dose were eliminated in subsequent analyses. Analysis of data from 
saline and the low dose of atropine, using a two-factor repeated measures ANOVA, 
revealed no significant main effect of dose (F(1,9) = .83, p = .39), but a significant 
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interaction between dose and block (F(4,36) = .10, p < .001). Thus, atropine appeared 
affect performance across the probability discounting task when testing all rats, resulting 
in poor decision making (Figure 5).  
 
 
 
 
 
 
 
 
 
 
 
As mentioned, treatment with all doses of atropine increased response omissions, 
preventing reliable whole group analysis in all rats with either the middle or high dose of 
atropine. Additionally due to a lack of sufficient data, split group analyses for the low 
dose could not be reported with confidence. Available data from this experiment do not 
support our predicted results that blockade of mAChRs would not significantly affect 
risky decision making, as assessed by the probability discounting task.  
 
 
Figure 5. Effects of atropine treatment on responding in 
the probability discounting task. Treatment with the low 
dose (black triangles) resulted in a significant shift in 
performance across the task, when compared to 
performance following treatment with saline (white 
circles). Effects of higher doses are not reported due an 
increase in response omissions. * p < .05. 
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Experiment 1 Summary and Discussion 
Results from Experiment 1 provide evidence suggesting that both nicotinic and 
muscarinic AChRs are involved in probabilistic cost-benefit decision making (Table on 
page 65). Activation of nAChRs following treatment with the high dose of nicotine 
increased preference for the large risky reward in all rats (although interestingly, both 
activation of nAChRs following treatment with the low dose of nicotine and blockade of 
nAChRs following treatment with the low dose of mecamylamine decreased preference 
for the large risky reward in rats that had high baseline levels of risky decision making). 
The role of mAChRs in probabilistic discounting was difficult to determine due to side 
effects that increased response omissions in the task. Results from the limited data 
obtained suggest that activation of mAChRs may affect probabilistic discounting; 
however, mAChR blockade may impair decision making when risk of reward loss is 
involved, resulting in disadvantageous decision making across the probability 
discounting task.  Experiments examining the effects of lower doses of mAChR agonists 
and antagonists that do not increase response omissions in the probability discounting 
task may address the question of whether or not mAChR are involved in probabilistic 
decision making. 
The effects of acute nicotine on probability discounting were the most prominent 
effects observed in Experiment 1. Increases in risky decision making following 
activation of nAChRs with the high dose of nicotine were observed in all rats, as well as 
in both risk-taking and risk-averse subgroups of rats. These increases in risky decision 
making observed following acute treatment with the high dose of nicotine do not support 
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our prediction that increases in nAChR activity would decrease risk-taking, suggesting 
instead that acute nAChR activation causes increases in risky decision making. 
Conversely, the finding observed with the low dose of nicotine in risk taking rats 
(decreased risky decision making) do support our predicted results, as well as research 
showing that nicotine treatment can enhance cognitive processes such as increases in 
attention and memory (Cutuli et al. 2008; Furey et al. 2000; Furey et al. 2008; Ricciardi 
et al. 2009). Furthermore, the findings observed following treatment with the low dose 
of nicotine suggest that the effects of nicotine on probabilistic decision making appear to 
depend on both nicotine dose and on baseline performance in the task.  
The mechanisms underlying the observed increase in risky decision making 
following treatment with the high dose of nicotine are unclear. As discussed, activation 
of nAChRs in the ventral tegmental area has been shown to increase reward salience and 
reinforcement, as well as incentive motivation (Picciotto et al. 2008; Zhang and Sulzer 
2004). These motivational increases may explain why rats treated with the high dose of 
nicotine were willing to continue to respond for larger amounts of food reward, even 
when that reward was accompanied by an increasing risk of loss. Further research 
investigating the increases in risky decision making observed in the probability 
discounting task following treatment with nicotine may help identify the neurobiological 
mechanisms underlying this effect. 
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EXPERIMENT 2. ROLE OF NICOTINIC AND MUSCARINIC RECEPTORS IN 
IMPULSIVE DECISION MAKING 
 
Experiment 2.1. Effects of the Acetylcholinesterase Inhibitor Donepezil on 
Performance in the Delay Discounting Task 
Experiment 2 used a design similar to that of Experiment 1; however, this 
experiment assessed performance on a “delay discounting” task and not in the 
probability discounting task. The delay discounting task characterizes the ability of 
delays in delivery to promote discounting of a larger reward and increase selection of a 
smaller immediate reward. This task is considered to assess impulsive behavior and the 
ability (or inability) to delay gratification (Evenden and Ryan 1996a). The first 
experiment in this set used systemic administration of the acetylcholinesterase inhibitor 
donepezil to determine its effects on performance in the delay discounting task. Based 
on data from our laboratory and research suggesting that increased acetylcholine levels 
increase prefrontal cortical-based cognition (Cutuli et al. 2008; Furey et al. 2000; Furey 
et al. 2008; Ricciardi et al. 2009), it was predicted that increased synaptic levels of 
acetylcholine would improve decision making as assessed by the delay discounting 
task. Specifically, it was predicted that donepezil treatment would decrease impulsive 
responding in high-impulsive rats, causing a shift in preference towards the larger, 
delayed reward. 
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Treatment 
In this experiment, the effects of the acetylcholinesterase inhibitor donepezil (0, 
0.3, 1.0, 3.0 mg/kg, i.p.), on performance in the delay discounting task, were 
investigated.  
Results 
No significant effects of donepezil treatment on response omissions, during test 
days in the delay discounting task, were observed (Table 2). Conversely, a significant 
effect of donepezil treatment on ITI locomotor activity, during test days in the delay 
discounting task, was observed (F(3,45) = 6.34, p < .01, Table 2). Post-hoc analyses 
revealed no significant effects when comparing ITI activity following treatment with 
only the low or middle dose of donepezil to that following treatment with saline; 
however, a significant decrease in activity was observed when comparing activity 
following saline treatment to that following treatment with the high dose of donepezil (p 
< .05).  
Analysis of 5 days of baseline responding prior to testing using a two-way 
repeated measures ANOVA showed no significant main effect of day (F(4,60) = .94, p = 
.45) or interaction between day and block (F(16,240) = .94, p = .52), but a significant effect 
of delay (F(4,60) = 78.72, P < .01). This suggests that animals were responding stably 
before treatment began and that they discounted the large reward as a function of the 
delay to its delivery.  
 
 39
Table 2. Effects of Cholinergic Drugs on Response Omissions and Locomotor 
Activity During Testing in the Delay Discounting Task. 
 Dose 
Donepezil 
Experiment  
2.1 
Nicotine 
Experiment 
2.2 
Oxotremorine
Experiment  
2.3 
Mecamylamine 
Experiment  
2.4 
Atropine 
Experiment  
2.5 
       
 
Mean Percent 
Choice Trials 
Omitted 
 
 
Veh 
Low 
Med 
Hi 
0.3% 
0.3% 
0.0% 
6.8% 
0.1% 
0.3% 
0.1% 
0.1% 
0.1% 
0.4% 
0.3% 
0.5% 
0.5% 
0.0% 
0.0% 
0.3% 
3.2% 
3.3% 
3.2% 
  7.2% * 
       
Mean ITI 
Locomotor Activity 
(beam breaks)  
breaks) 
Veh 
Low 
Med 
Hi 
2491 
2533 
2558 
 1804 * 
2883 
3006 
3729 
  3780 * 
3136 
3175 
3278 
  2748 * 
2277 
2325 
2219 
2209 
2372 
2348 
2311 
      1815 * 
           
* = significantly different from Veh 
 
The effects of all doses of donepezil on the performance of rats in the delay 
discounting task were assessed using a two-factor repeated measures ANOVA. No 
significant main effect of dose (F(3,42) = .26, p = .86) or interaction between dose and 
block (F(12,168) = 1.33, p = .20) were observed. Thus, donepezil does not appear to affect 
performance in the delay discounting task, when testing all rats (Figure 6(A)).  
To examine how donepezil administration interacted with baseline levels of 
impulsivity, animals from this experiment were split into non-impulsive and impulsive 
groups based on whether they fell above or below the median percentage of choices 
(averaged across blocks) of the large, delayed reward, during the 5 days of stable 
responding immediately prior to testing. The effects of all doses of donepezil on the 
performance of non-impulsive rats in the delay discounting task were assessed using a 
two-factor repeated measures ANOVA. In non-impulsive rats, no significant main effect 
 40
of dose (F(3,18) = .86, p = .48) or interaction between dose and block (F(12,72) = .95, p = 
.50) was observed. Thus, donepezil does not appear to affect impulsive choice in rats 
with low baseline levels of impulsivity (Figure 6(B)).  
 
(A)        
 
 
 
 
 
(B)         (C) 
 
 
 
 
 
 
 
 
A two-factor repeated measures ANOVA was again used to assess the effects of 
all doses of donepezil on the performance of impulsive rats in the delay discounting task. 
There was no significant main effect of dose (F(3,21) = .24, p = .87) or interaction 
  
Figure 6. Effects of donepezil treatment on responding in the delay discounting task. (A) 
Treatment with all doses of donepezil did not significantly affect performance in the 
delay discounting task, when compared to performance following treatment with saline. 
(B) Treatment with all doses of donepezil did not significantly shift the performance of 
non-impulsive rats in the delay discounting task when compared to performance 
following treatment with saline. (C) No significant shift in performance was observed in 
risk-averse rats when treated with donepezil and comparing to performance following 
treatment with saline.  
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between dose and block (F(12,84) = .88, p = .57). Thus, donepezil did not appear to 
significantly alter impulsive choice in rats with high baseline levels of impulsivity 
(Figure 6(C)). Results from this study do not support our predictions (based on 
Experiment 1.1) that increases in AChR activity would decrease impulsive choice, as no 
effects were observed in either the full or split group analyses. Together with the 
findings of Experiment 1.1, these findings suggest that increases in synaptic levels of 
acetylcholine following treatment with donepezil affect risky decision making, but not 
impulsive decision making. 
 
Experiment 2.2. Effects of the Nicotinic Receptor Agonist Nicotine on Performance 
in the Delay Discounting Task 
The second experiment in this set used systemic administration of the non-
selective nAChR agonist nicotine, to determine its effects on performance in the delay 
discounting task and impulsive decision making. Data from Experiment 1.2 suggest that 
the effect of nicotine treatment on preference for a larger reward that is disadvantageous 
due to risk of reward omission is dependent on both nicotine dose and baseline 
performance. While treatment with a high dose of nicotine increased risky choice in all 
rats, treatment with a low dose of nicotine decreased risky choice in rats with high 
baseline levels of risky decision making. Based on the data from Experiment 1, as well 
as research from Dallery et al. showing increases in impulsive choice following acute 
nicotine treatment, it was predicted that activation of nAChRs with a low dose of 
nicotine would decrease disadvantageous, impulsive decision making in the delay 
 42
discounting task, while treatment with a high dose would increase impulsive decision 
making. Decreased impulsive choice would be evident by a shift in preference toward 
the larger delayed reward, while increases in impulsive choice would be evident by a 
shift in preference toward the smaller, immediate reward following acute treatment with 
the nAChR agonist nicotine.  
Treatment 
Experiment 2.2 used the same experimental design and statistical analysis as 
Experiment 2.1 described above, except that the effects of the nAChR agonist nicotine 
(0, 0.1, 0.3, 1.0 mg/kg, s.c.) on delay discounting were investigated instead.  
Results 
No significant effect of nicotine treatment on response omissions, during test 
days in the delay discounting task, was observed (Table 2). Conversely, a significant 
effect of nicotine treatment on ITI locomotor activity, during test days in the delay 
discounting task, was observed (F(3,45) = 2.91, p < .05, Table 2). Post-hoc analyses 
revealed no significant effects when comparing ITI activity following treatment with 
only the low dose of nicotine to that following treatment with saline; however, 
significant increases in activity were observed when comparing activity following saline 
treatment to that following treatment with either the middle or high dose of nicotine (ps 
< .05).  
Analysis of 5 days of baseline responding prior to testing using a two-way 
repeated measures ANOVA showed no significant main effect of day (F(4,56) = 1.78, p = 
.15) or interaction between day and block (F(16,224) = 1.67, p = .05), but a significant 
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effect of block (F(4,56) = 76.89, p < .01), suggesting that responding was stable prior to 
nicotine treatment. The effects of all doses of nicotine on the performance of rats in the 
delay discounting task were assessed using a two-factor repeated measures ANOVA. No 
significant main effects of dose (F(3,45) = 1.85, p = .15) or interaction between dose and 
block (F(12,180) = .99, p = .46) were observed. Thus, nicotine does not appear to affect 
impulsive choice when testing all rats (Figure 7(A)).  
As with the donepezil experiment (Experiment 2.1), animals were split into non-
impulsive and impulsive groups based on whether they fell above or below the median 
percent choice (averaged across blocks) of the large, delayed reward, during the 5 days 
of stable responding immediately prior to testing. The effects of all doses of nicotine on 
the performance of non-impulsive rats in the delay discounting task were assessed using 
a two-factor repeated measures ANOVA. No significant main effect of dose (F(3,21) = 
.53, p = .67) or interaction between dose and block (F(12,84) = .93, p = .52) were 
observed. Thus, nicotine does not appear to affect impulsivity in rats with low baseline 
levels of impulsive choice (Figure 7(B)).  
The effects of all doses of nicotine on the performance of impulsive rats in the 
delay discounting task were also assessed using a two-factor repeated measures 
ANOVA. A significant main effect of dose (F(3,21) = 3.32, p < .05), but no significant 
interaction between dose and block (F(12,84) = .70, p = .75) was observed. Post-hoc 
comparisons of performance following treatment with each dose of nicotine to 
performance following saline treatment revealed no significant shifts in choice 
preference in the delay discounting task, although treatment with the high dose did result 
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in a modest increase in preference for the large delayed reward (p = .06), when 
compared to saline controls. Thus, nicotine appeared to modestly decrease impulsive 
choice in rats with high baseline levels of impulsive choice (Figure 7(C)). 
 
                        (A)        
 
 
 
 
 
(B)                                          (C) 
 
 
 
 
 
 
 
 
 
 
Figure 7. Effects of nicotine treatment on responding in the delay discounting task. (A) 
Analysis of treatment with all doses of nicotine suggests no significant shifts in performance 
on the delay discounting task, when compared to performance following treatment with saline. 
(B) Treatment with all doses of nicotine did not significantly shift the performance of non-
impulsive rats in the delay discounting task when comparing to performance following 
treatment with saline. (C) Treatment with all doses of nicotine significantly shifted the 
performance of impulsive rats in the delay discounting task, when compared to saline controls. 
Post-hoc analyses revealed no significant between group differences, when comparing 
performance in the delay discounting task following treatment with nicotine to performance 
following treatment with saline. * p < .05.
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Activation of nAChRs did not affect performance in the delay discounting task 
when analyzing performance in all or non-impulsive rats; however, nicotine did appear 
to decrease impulsive choice in impulsive rats. It should be noted, however, that the 
significance in these results was limited to the omnibus ANOVA and were not obtained 
with between-group analyses. Although results from this study did not clearly support 
our predictions (based on Experiment 1.2 and Dallery and Locey 2005) that activation of 
nAChRs with a low dose of nicotine would decrease impulsive decision-making, while 
treatment with a high dose would increase impulsive decision making, they do suggest 
that nAChRs are involved in impulsive decision making.  
The observed findings are contrary to the increases in impulsive choice found by 
Dallery et al.; however, this may be due to differences between the fixed delay 
discounting task used in these experiments and the adjusting delay procedure used by 
Dallery et al. In our fixed delay task, impulsive choice is measured as a percentage of 
preference for immediate versus delayed rewards, while in the adjusted delay procedure 
impulsive choice is represented by an indifference point that indexes the value of a 
delayed reward by adjusting the delay to large reward. Similar opposing effects in delay 
discounting have also been observed in different experiments, following treatment with 
acute amphetamine (Cardinal et al. 2000a; de Wit et al. 2002; Stanis et al. 2008; Wade et 
al. 2000).  
Research has shown increases in cognitive function following acute nicotine 
administration (Cutuli et al. 2008; Experiment 1.2; Furey et al. 2000; Furey et al. 2008; 
Ricciardi et al. 2009). Enhanced cognitive processes may explain why rats that had high 
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baseline levels of impulsive choice were willing to wait for a larger, more advantageous 
food reward following nicotine treatment. As mentioned, nAChR are also involved in 
reward motivation. Given that nicotine increased preference for the larger reward in both 
the probabilistic and delay discounting task, an alternative explanation for both sets of 
findings is that the effects in the delay discounting task may result from acute increases 
in motivation for the larger reward, even when temporal costs are increased over time. 
Notably, research investigating the effects of amphetamine on impulsive choice, using 
the same fixed delay design used in this experiment, has shown results similar to that 
seen here with nicotine (Setlow et al. 2009; Slezak and Anderson 2009). Like 
amphetamine, nicotine can cause increases in mesolimbic dopamine release, suggesting 
that increases in mesolimbic dopamine levels may underlie these drug effects on cost-
benefit decision making through increases in motivation for rewards and reward related 
cues. Further research investigating the increases in preference for the larger reward 
observed in the delay discounting (and probability discounting) task following treatment 
with nicotine may help identify the neurobiological mechanisms underlying this effect.  
 
Experiment 2.3. Effects of the Muscarinic Receptor Agonist Oxotremorine on 
Performance in the Delay Discounting Task 
The third experiment in this set used systemic administration of the non-selective 
mAChR agonist oxotremorine, to determine its effects on performance in the delay 
discounting task and impulsive decision making. Due to motoric impairments that 
resulted in a large number of trial omissions in the task following treatment with the high 
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dose of oxotremorine in Experiment 1.3, a lower dose replaced the highest dose used in 
the probability discounting task. Based on limited data from Experiment 1.3, it was 
predicted that activation of mAChRs following systemic administration of oxotremorine 
would not affect performance in the delay discounting task when assessed in either full 
or impulsive-split analyses.  
Treatment 
Experiment 2.3 used the same experimental design and statistical analysis as 
Experiment 2.2 described above, however, in this experiment the effects of the mAChR 
agonist oxotremorine (0, 0.003, 0.01, 0.03 mg/kg, i.p.) were investigated instead.  
Results 
No significant effect of oxotremorine treatment on response omissions, during 
test days in the delay discounting task, was observed (Table 2). Conversely, a significant 
effect of oxotremorine treatment on ITI locomotor activity, during test days in the delay 
discounting task, was observed (F(3,45) = 4.07, p < .05, Table 2). Post-hoc analyses 
revealed no significant effects when comparing ITI activity following treatment with 
only the low or middle dose of oxotremorine to that following treatment with saline, and 
a near significant decrease in ITI activity, when comparing activity following treatment 
with the high dose of oxotremorine to that following treatment with saline (p = .07).  
Analysis of 5 days of baseline responding prior to testing using a two-way 
repeated measures ANOVA showed no significant main effect of day (F(4,56) = 1.70, p 
=.16) or interaction between dose and block (F(16,224) = 1.37, p =.16), but a significant 
effect of probability (F(4,56) = 73.80, p < .01). This suggests that animals were responding 
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stably before treatment began. Analysis of data from all doses of oxotremorine, using a 
two-factor repeated measures ANOVA, revealed no significant main effect of dose 
(F(3,45) = 2.37, p = .08) or interaction between dose and block (F(12,180) = 1.38, p = .18). 
Thus, oxotremorine does not appear to affect impulsive choice, when testing all rats 
(Figure 8(A)). 
As in previous experiments, animals were split into non-impulsive and impulsive 
groups based on whether they fell above or below the median percent of choice for the 
large, delayed reward, totaled across blocks. The effects of all doses of oxotremorine on 
the performance of non-impulsive and impulsive rats, in the delay discounting task, were 
assessed using a two-factor repeated measures ANOVA. Results indicate no main effect 
of dose (F(3,21) = .82, p = .50), but a significant interaction between dose and block 
(F(12,84) = 2.26, p < .05), on performance in the delay discounting task with non-
impulsive rats. Post-hoc comparisons of performance following treatment with each dose 
of oxotremorine to performance following saline treatment resulted in no significant 
shifts in choice preference. Nonetheless, oxotremorine did appear to increase impulsive 
choice in rats with low baseline levels of impulsive choice (Figure 8(B)). 
 A significant main effect of dose (F(3,21) = 3.71, p < .05), but no significant 
interaction effect (F(12,84) = 1.26, p = .26) on performance was observed in impulsive 
rats, again when comparing all doses of oxotremorine. Although post-hoc comparisons 
of performance following treatment with each dose of oxotremorine to performance 
following saline treatment resulted in no significant shifts in choice preference, 
treatment with both the low and middle dose did cause moderate increases in preference 
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for the large delayed reward, when compared to choice preference following saline 
treatment (ps = .08). Results suggest that oxotremorine may modestly decrease 
impulsive choice in rats with high baseline levels of impulsive choice (Figure 8(C)).  
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Figure 8. Effects of oxotremorine treatment on responding in the delay discounting task. 
(A) Analysis of treatment with all doses of oxotremorine suggests no significant shift in 
performance on the delay discounting task, when compared to performance following 
treatment with saline. (B) Treatment with all doses of oxotremorine resulted in a 
significant interaction effect, represented by a shift in performance across the delay 
discounting task in non-impulsive rats. Post-hoc analyses reveal no significant effects 
when comparing performance following treatment of each dose of oxotremorine to 
performance after saline treatment. (C) Impulsive rats showed a significant main effect 
of dose represented by a shift in performance, as a result of dose of oxotremorine. 
Similar to non-impulsive rats, no main effects were found when comparing performance 
following each dose to performance following saline treatment. * p < .05. 
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Results from this experiment do not support our predicted results that 
oxotremorine would not affect impulsive decision making. Although activation of 
mAChRs did not significantly affect performance in the delay discounting task when 
assessing all rats, significant shifts in reward preference were observed in the split group 
analyses (in both impulsive and non-impulsive rats). Similar to results seen with 
donepezil in the probability discounting task, the effect of oxotremorine was dependent 
on baseline impulsive choice, in that the direction of the shift in reward preference was 
different for the impulsive and non-impulsive group. These group differences may, in 
turn, be dependent on intrinsic differences in cholinergic function (see Experiment 3). 
Results from this experiment suggest that mAChR are involved in the discounting of 
delayed rewards. 
 
Experiment 2.4. Effects of the Nicotinic Receptor Antagonist Mecamylamine on 
Performance in the Delay Discounting Task 
The fourth experiment in this set used systemic administration of the non-
selective nAChR antagonist mecamylamine, to determine its effects on impulsive 
decision making. Based on results from Experiment 2.2 showing that nAChR activation 
modestly increases choice of the large delayed food reward in rats with low baseline 
levels of impulsive choice, it was predicted that blockade of nAChRs would decrease 
preference for the large delayed reward, and increase impulsive choice. This would be 
evident by a decrease in preference for the large delayed reward. 
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Treatment 
Experiment 2.4 used the same experimental design and statistical analysis as 
Experiment 2.3 described above. However, the effects of the nAChR antagonist 
mecamylamine (0, 0.5, 1, 2 mg/kg, s.c.) on performance in the delay discounting task 
were investigated instead. 
Results 
No significant effects of mecamylamine treatment on response omissions and 
locomotor activity, during test days in the delay discounting task, were observed (Table 
2). Analysis of 5 days of baseline responding prior to testing using a two-way repeated 
measures ANOVA showed no significant main effect of day (F(4,60) = 1.37, p = .26) or 
interaction between day and block (F(16,240) = .97, p = .49), but a significant effect of 
probability (F(4,60) = 91.46, p < .01), indicating that animals were responding stably 
before treatment began.  
The effects of all doses of mecamylamine on the performance of rats in the delay 
discounting task were assessed using a two-factor repeated measures ANOVA. No 
significant main effects of dose (F(3,45) = 2.68, p = .06) or interaction between dose and 
block (F(12,180) = .94, p = .51) were observed. However, treatment with the highest dose 
of mecamylamine did appear to cause a slight increase in preference for the large 
delayed reward. Results suggest mecamylamine does not significantly affect impulsive 
choice, when testing all rats (Figure 9(A)).  
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Animals were again split into non-impulsive and impulsive groups based on 
whether they fell above or below the median percent choice (averaged across blocks) of 
the large, delayed reward, during the 5 days of stable responding immediately prior to 
testing. The effects of all doses of mecamylamine on the performance of non-impulsive 
rats in the delay discounting task were assessed using a two-factor repeated measures 
Figure 9. Effects of mecamylamine treatment on responding in the delay discounting task. 
(A) Analysis of treatment with all doses of mecamylamine suggests no significant shift in 
performance on the delay discounting task, when compared to performance following 
treatment with saline. (B) Treated with all doses of mecamylamine did not significantly 
shift the performance of non-impulsive rats in the delay discounting task, when compared 
to performance following treatment with saline. (C) Treatment with all doses of 
mecamylamine significantly shifted performance in a dose dependent manner, in the delay 
discounting task, when compared to performance following treatment with saline. Post-
com comparisons show no significant difference in choice preference, when comparing 
performance following each individual dose of mecamylamine, to that following saline. * p 
< .05 
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ANOVA. No significant main effect of dose (F(3,21) = 1.02, p = .40) or interaction 
between dose and block (F(12,84) = 1.67, p = .09) were observed. Interestingly, similar to 
results seen with all rats, treatment with the highest dose of mecamylamine did cause a 
slight increase in preference for the large delayed reward. Nonetheless, statistical 
analysis suggests that mecamylamine does not appear to affect impulsive choice in rats 
with low baseline levels of impulsive choice (Figure 9(B)).  
The effects of all doses of mecamylamine on the performance of impulsive rats 
in the delay discounting task were also assessed using a two-factor repeated measures 
ANOVA. A significant main effect of dose (F(3,21) = 5.47, p < .01), but no significant 
interaction between dose and block (F(12,84) = .91, p = .54) were observed. Post-hoc 
comparisons of performance following treatment with each dose of mecamylamine to 
performance following saline treatment resulted in no significant shift in choice 
preference. Nonetheless, results suggest that mecamylamine can affect impulsive choice 
in rats with high baseline levels of impulsivity (Figure 9(C)). 
Results from this experiment do not support our predictions that blockade of 
nAChR would decrease preference for the large delayed reward. Together with the 
findings of Experiment 1.4, these data suggest that acute treatment with mecamylamine 
causes decreased preference for large, risky food rewards in risk-taking rats in the 
probability discounting task. Furthermore, while mecamylamine clearly affected 
performance in the delay discounting task, direction of the effect on performance is not 
clear. Pharmacological activation and blockade of nAChRs appear to modulate cost-
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benefit decision making; however, more research is needed to fully identify the role of 
nAChRs. 
 
Experiment 2.5. Effects of the Muscarinic Receptor Antagonist Atropine on 
Performance in the Delay Discounting Task 
The fifth experiment in this set used systemic administration of the non-selective 
mAChR antagonist atropine to determine its effects on impulsive decision making. Due 
to problems in Experiment 1.5 with task performance in the probability discounting task 
following treatment with the middle and high dose of atropine, two lower doses of 
atropine replaced the two higher doses used in Experiment 1.5. Based on the lack of 
effect on risk-taking following treatment with the lowest dose of atropine, it was 
predicted that blockade of mAChR would not affect performance in the delay 
discounting task when assessing rats jointly or as impulsive-split groups. Blockade of 
mAChR may also interfere with behavioral participation in the task via motoric or 
cognitive impairments. These effects would be evident as an increase in response 
omissions, as seen with atropine in the probability discounting task. 
Treatment 
Experiment 2.5 used the same experimental design and statistical analysis as in 
Experiment 2.4 described above. However, the effects of the mAChR antagonist 
atropine (0, 0.03, 0.1, 0.3 mg/kg, i.p.) were investigated instead.  
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Results 
 Significant effects of atropine treatment on response omissions and ITI 
locomotor activity during test days in the delay discounting task were observed (Table 
2). A significant effect of atropine dose was observed when comparing response 
omissions during treatment days (F(3,45) = 8.89, p < .01). Post-hoc analyses revealed no 
significant effects when comparing response omissions following treatment with only 
the low or middle dose of atropine to that following treatment with saline; however, 
results do show that response omissions significantly increased when comparing 
omissions following treatment with the high dose of atropine to that following treatment 
with saline (p < .01). Effects of the high dose of atropine on response omissions were 
carried by only a few rats (3 of 16 rats omitted 7 or more trials within a block), allowing 
for group data analysis. A significant effect of atropine dose was observed when 
comparing ITI locomotor activity during treatment days (F(3,45) = 4.03, p < .05). Post-hoc 
analyses revealed no significant effects when comparing ITI activity following treatment 
with only the low or middle dose of atropine to that following treatment with saline; 
however, results do show that ITI activity significantly decrease when comparing 
activity following treatment with the high dose of atropine to that following treatment 
with saline (p < .01).  
Analysis of 5 days of baseline responding prior to testing using a two-way 
repeated measures ANOVA showed no significant main effect of day (F(4,56) = .89, p = 
.48) or interaction between day and block (F(16,224) = .68, p = .81), but a significant effect 
of probability (F(4,56) = 66.71, p < .01). This suggests that animals were responding 
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stably before treatment began. Analysis of data from all doses of atropine, using a two-
factor repeated measures ANOVA, revealed a significant main effect of dose (F(3,36) = 
6.81, p < .01) and interaction between dose and block (F(12,144) = 2.74, p < .01). Post-hoc 
analysis using a two-way repeated measure ANOVA reveal that although treatment with 
the low or middle dose of atropine does not appear to significantly affect choice 
preference in the delay discounting task, treatment with the high dose of atropine results 
in a significant decrease in preference for the large delayed reward, when compared to 
choice preference following treatment with saline (p < .05). Thus, treatment with the 
mAChR antagonist atropine results in an increase in impulsive choice across all rats 
(Figure 10(A)). 
As in previous experiments, animals were split into impulsive and non-impulsive 
groups based on whether they fell above or below the median percent of choice for the 
large, delayed reward, totaled across blocks. A two-factor repeated measures ANOVA 
was used to assess the effects of all doses of atropine on the performance of rats with 
low baseline levels of impulsive choice in the delay discounting task. There was a 
significant main effect of dose (F(3,18) = 3.15, p = .05) and interaction between dose and 
block (F(12,72) = 1.98, p < .05) observed (Figure 10(B)). Post-hoc analyses revealed no 
significant effect on choice preference following treatment with each dose of atropine; 
however, treatment with the highest dose of atropine did produce a near significant 
decrease in preference for the large delayed reward (p = .06).  
 
 
 57
Delay Discounting
0 4 8 16 32
0
25
50
75
100
Saline
0.03 mg/kg Atropine
0.1 mg/kg Atropine
0.3 mg/kg Atropine
Delay to Delivery of Large Reward (s)
C
ho
ic
e 
of
 L
ar
ge
 R
ew
ar
d
(m
ea
n
+
se
m
, %
)
(A)  
 
  
 
 
 
(B)                                   (C) 
 
 
 
 
 
 
 
 
 
 
 
 
The effects of all doses of atropine on the performance of non-impulsive rats in 
the delay discounting task were assessed using a two-factor repeated measures ANOVA. 
In rats with high baseline levels of impulsive choice, a significant main effect of dose 
Figure 10. Effects of atropine treatment on responding in the delay discounting task. (A) 
Analysis of treatment with all doses of atropine, in all rats, suggests a significant shift in 
performance on the delay discounting task when compared to performance following 
treatment with saline. Post-hoc analyses revealed that treatment with the high dose (black 
circles) significantly decreased preference for the large delayed reward when compared to 
treatment with saline (white circles). (B) Analysis of treatment with all doses of atropine, in 
impulsive, suggests a significant shift in performance on the delay discounting task when 
compared to performance following treatment with saline. Post-hoc analyses revealed no 
significant effect of each individual dose on choice preference, when compared to treatment 
with saline (white circles). (C) Analysis of treatment with all doses of atropine, in all rats, 
suggests a significant shift in performance on the delay discounting task when compared to 
performance following treatment with saline. Post-hoc analyses revealed that treatment with 
the low and high dose (black triangles and circles, respectively) significantly decreased 
preference for the large delayed reward when compared to treatment with saline (white 
circles). * p <. 05 
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(F(3,18) = 4.29, p < .05) and interaction between dose and block (F(12,72) = 3.08, p < .01) 
was observed. Post-hoc analyses revealed a near significant decrease in preference for 
the large delayed reward when comparing performance following treatment with the 
middle dose of atropine to that of saline (p = .07). Interestingly, treatment with the low 
dose of atropine revealed a significant interaction between dose and block (p < .05), 
showing a decrease in choice for the large delayed reward for the first 3 blocks, then 
increasing choice for the large delayed reward for blocks 4 and 5. Furthermore, 
treatment with the high dose of atropine resulted in a significant decrease in preference 
for the large delayed reward (p < .05). The results suggest that treatment with atropine 
significantly increases impulsive choice in rats with high baseline levels of impulsivity 
(Figure 10(C)). Results from this experiment do not support our predicted results that 
blockade of mAChRs would not affect performance in the delay discounting task in all 
rat or split group analysis, and suggest that blockade of mAChRs significantly increases 
impulsive choice. 
 
Experiment 2.6. Effects of the Nicotinic Receptor Agonist Nicotine on Response 
Perseveration in the Probability Discounting Task 
During the course of completing Experiment 2, a number of studies investigating 
probabilistic discounting were conducted at the University of British Columbia, and 
published by principal investigator Stan Floresco. In these studies, Floresco and 
colleagues showed that, similar to our effects following treatment with acute nicotine 
(Experiment 1.2), systemic acute injections of amphetamine (St Onge et al. 2010), as 
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well as inactivation of the medial prefrontal cortex (St. Onge and Floresco 2009), can 
cause increases in preference for a large risky reward in a probability discounting task in 
which the probability of large reward delivery descends across a test session (as in 
Experiment 1). Interestingly, their studies further demonstrate that when the order of 
probabilities is reversed (probability of reward delivery ascends across a test session), 
these same manipulations lead rats to prefer the smaller safe reward relative to controls. 
The authors suggest that increases in choice for the large risky reward in the probability 
discounting task with descending probabilities of reward delivery may be due to 
response perseveration rather than actual increased preference for large risky rewards. In 
Experiment 1, risky decision making was assessed with decreasing probabilities of 
delivery of the large reward across a test session. Following treatment with nicotine, rats 
began the task by selecting the large reward, and then maintained their preference for 
this initial selection longer than when testing occurred following saline treatment. 
Therefore, based on the findings of Floresco and colleagues, it may be argued that the 
maintained preference for the initially chosen large reward observed following acute 
nicotine injections (Experiment 1.2) may have occurred, at least in part, as a result of 
drug-induced response perseveration.  
To address this issue, the rats used in Experiment 2 were tested in several control 
experiments. In the first control experiment, the effects of nicotine on probability 
discounting were tested in the descending probability version of the probability 
discounting task used in Experiment 1. This experiment was necessary to verify that 
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similar results as those seen in our initial experiment testing the effects of nicotine on 
probability discounting (Experiment 1.2) could be replicated with this group of rats.  
Following this initial control experiment, the effects of the highest dose of 
nicotine was tested in a version of the probability discounting task in which the 
probabilities of delivery of the large reward ascended as the test session progressed. 
With this order of presentation of reward probabilities, animals will produce an inverted 
version of the response curve obtained with descending probabilities of large reward 
delivery. Since the probability of the large reward begins at 0%, rats will initially chose 
the small guaranteed reward; however, as the task progresses and the probability of 
delivery of the large reward increases, rats will shift their preference over to the large 
risky reward (Floresco and Whelan 2009). If nicotine causes perseverative responding, 
then it should decrease rats’ preference for the large reward as the probability of its 
delivery increases. However, if nicotine causes increased preference for large rewards, 
then the opposite pattern of behavior should emerge.  
A third control experiment was used to further characterize potential nicotine-
induced increases in response perseveration. In this experiment we used a within-session 
shift task, in which the large reward shifts within a single test session from being 
delivered (100% probability of delivery) for the first two blocks, to not being delivered 
at all (0% probability) in blocks 3, 4, and 5. If nicotine induces response perseveration, 
then following treatment with nicotine, animals should continue to choose the large 
reward significantly more during blocks 3, 4 and 5, when compared to performance 
following saline treatment. This simpler version of the task provides a more stringent 
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test of response perseveration in the absence of any requirements for calculating changes 
in reward probabilities.  
As discussed, activation of nAChRs in the ventral tegmental area has been shown 
to increase reward salience and reinforcement, as well as incentive motivation (Picciotto 
et al. 2008; Zhang and Sulzer 2004). These reported nAChR activity-dependent 
increases in reward salience and reinforcement may explain why acute treatment with 
nicotine increased preference for the larger, albeit risky reward, in the probability 
discounting task. Based on these findings, it was predicted that nicotine treatment would 
increase preference for the large risky reward in both the descending and ascending 
probability discounting task, as well as the within-session shift task. 
Treatment 
Following completion of Experiment 2.5, rats from this experiment were trained 
in the probability discounting task with descending probabilities of large reward delivery 
(100, 50, 25, 12.5, 0%) until stable responding was achieved. Rats were then treated with 
nicotine using the same within subject design and discounting task used in Experiment 1; 
however, in this experiment only the highest dose of nicotine was used, limiting 
treatment to only 2 days. After completion of the descending large reward delivery 
probability version of the task used in Experiment 1, rats were trained and tested 
similarly in the probability discounting task with ascending probabilities of large reward 
delivery (0, 12.5, 25, 50, 100%), using the same protocol. Finally, upon completion of 
the ascending probability task, rats were again tested using the same protocol with a 
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within-session shift test, in which the delivery of the large reward switched from 
guaranteed to not delivered (100, 100, 0, 0, 0%). 
Results 
Analysis of 5 days of baseline responding prior to testing in the descending 
probability discounting task using a two-way repeated measures ANOVA showed no 
significant main effect of day (F(4,60) = 1.63, p = 1.78) or interaction between day and 
block (F(16,240) = .68, p = .81), but a significant effect of probability (F(4,60) = 296.15, p < 
.01). This suggests that animals were responding stably before treatment began. Analysis 
of data using a two-factor repeated measures ANOVA revealed a significant main effect 
of dose (F(1,15) = 19.83, p < .05) and interaction between dose and block (F(4,60) = 5.74, p 
< .01). As in Experiment 1.2 the high dose of nicotine appeared to affect risky choice by 
increasing preference for the initially chosen large risky reward, when testing all rats 
with descending probabilities of delivery of the large risky reward (Figure 11(A)).  
Analysis of 5 days of baseline responding prior to testing in the ascending 
probability discounting task using a two-way repeated measures ANOVA, showed a 
significant man effect of day (F(4,60) = 5.52, p < .01) and block (F(4,60) = 330.16, p < .01), 
as well as an interaction between day and block (F(16,240) = 2.31, p < .01). Analysis of 
data in the ascending probability discounting task revealed a significant main effect of 
dose (F(1,15) = 11.07, p < .01) and interaction between dose and block (F(4,60) = 5.49, p < 
.01). Interestingly, when testing with ascending probabilities of large risky reward 
delivery, the high dose of nicotine appeared to affect risky choice not by increasing 
preference for the larger, risky reward (as we saw with the descending probabilities), but 
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by increasing preference for the smaller guaranteed reward that was initially preferred 
(Figure 11(B)). Finally, analysis of data in the within-session perseveration test revealed 
a significant main effect of dose (F(1,13) = 23.75, p < .01) and interaction between dose 
and block (F(4,52) = 22.13, p < .01). The high dose of nicotine appeared to maintain 
preference for the larger, initially chosen reward when compared to treatment with saline 
(as seen with the descending probabilities), by increasing preference for the large reward 
option during blocks when it was not delivered (Figure 11(C)).  
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Figure 6. Effects of nicotine on within-session response perseveration. (A) Treatment with 
nicotine (black circles) resulted in a significant shift in performance in rats when compared to 
performance following treatment with saline (white circles), in the probability discounting task 
with descending probabilities of delivery of the large reward. (B) Treatment with nicotine (black 
circles) resulted in a significant shift in performance in rats when compared to performance 
following treatment with saline (white circles), in the probability discounting task with ascending 
probabilities of delivery of the large reward. (C) Treatment with nicotine (black circles) resulted 
in a significant shift in performance in rats when compared to performance following treatment 
with saline (white circles), in a within-session perseveration test. * p < .05.
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Results from this experiment do not support our predicted results that treatment 
with nicotine would cause an increase in choice of the large risky reward. The 
experiment instead showed that nicotine treatment increased preference for the initially 
selected reward in all tasks, regardless of whether that reward was the small safe reward 
(ascending probabilities) or the large risky reward (descending probabilities, within-
session shift). These findings suggest that the increases in choice of the large delayed 
reward following treatment with the high dose of nicotine in Experiment 1.2 and 2.6 are 
not simply due to increases in the salience and/or reinforcement value of reward, but 
may be due, at least in part, to increases in perseverative responding. The results of this 
experiment identify a need to consider issues of behavioral perseveration in tasks 
assessing the effects of nicotine on the discounting of probabilistic rewards. 
 
Experiment 2 Summary and Discussion 
Results from Experiment 2 suggest that both nicotinic and muscarinic AChRs are 
involved in cost-benefit decision making involving delays (Table 3). Activation of 
nAChRs appeared to increased preference for the large delayed reward in rats with high 
baseline levels of impulsive choice; however, this directionality was not statistically 
confirmed, as a lack of between group effects was observed. Results from this 
experiment also demonstrate that blockade of nAChRs by all doses of mecamylamine 
caused significant shifts in preference for delayed rewards in rats with high baseline 
levels of impulsive choice; however, a lack of significant effects by any individual dose 
made the directionality of these effects difficult to interpret. Interestingly, a recent study 
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with humans showed that oral administration of mecamylamine caused decreases in 
tolerance for delays when testing patients with ADHD (high baseline levels of impulsive 
choice) in the Choice Delay Task, resulting in even higher levels of impulsivity (Potter 
et al. 2009). Again, the data suggests that the effects of nicotinic receptor agonists and 
antagonists on discounting of delayed rewards may depend on both dose used and 
baseline levels of impulsive choice.  
 
Table 3. Summary of Cholinergic Behavioral Pharmacology Experiments 
 Donepezil (AChE-) 
Nicotine 
(nAChR+) 
Oxotremorine 
(mAChR+) 
Mecamylamin
e 
(nAChR-) 
Atropine 
(mAChR-) 
      
Effects on Risky 
Choice  
(% choice of large 
reward in probability 
discounting task) 
Affected 
behavior in all 
rats, direction 
unclear. 
Decreased in 
risk-taking rats 
Increased in 
all rats No effects 
Decreased in 
risk-taking rats 
Decreased 
then increased 
in all rats 
      
Effects on Impulsive 
Choice  
(% choice of small 
reward in delay 
discounting task) 
No Effects 
Affected 
behavior in 
impulsive rats, 
direction 
unclear 
Affected 
behavior in 
impulsive and 
non-impulsive 
rats, direction 
unclear. 
Affected 
behavior in 
impulsive rats, 
direction 
unclear 
Increased in  
all rats 
      
  
 
Investigation of the role of mAChRs in delay discounting suggests that these 
receptors are also involved in impulsive decision making. The effects of mAChR 
activation by oxotremorine were limited to our analysis of all treatment doses in split 
group analysis. Although it appears that oxotremorine increases impulsive choice in non-
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impulsive rats and decreases it in impulsive rats, because the effects by individual doses 
were not seen, the directionality of any effects of oxotremorine was difficult to 
determine. Interestingly, the most prominent effect on delay discounting was observed 
following blockade of mAChR by atropine. Results show that acute injections of the 
high dose of atropine decreased impulsive choice in all rats. Prior to these experiments, 
the role of muscarinic receptors in delay discounting had not been investigated. These 
findings are very different from those observed following nAChR activation and may 
occur as a result of differences in the structure and function of the cholinergic receptor 
type. While activation of ionotropic nAChRs has been shown to have an excitatory 
effect on cellular processes, metabotropic mAChR have been shown to be both 
excitatory and inhibitory. This suggests that mAChR may play a modulatory role in cost-
benefit decision making. The complex organization of mAChR subtypes complicates the 
interpretation of our data and highlights the need for more research investigating the 
biological mechanisms of each mAChR subtype and how they can affect cost-benefit 
decision making. 
The effects of acute systemic injections of nicotine on response perseveration 
within the probability discounting task were also examined in Experiment 2. In a version 
of the probabilistic discounting task with ascending probabilities of reward delivery, 
nicotine caused rats to choose the smaller safer reward significantly more than with 
saline. Similarly, when testing choice preference in a within-session shift task, rats 
continued to respond on the lever that initially yielded a larger reward, even when such 
responding yielded no reward. The results from this control experiment suggest that our 
 67
initially observed effects of nicotine on probabilistic discounting (increased preference 
for the large, risky reward), may be due to nicotine-induced increases in response 
perseveration. The findings from our control experiments also rule out several 
alternative explanations for our initially observed effects of nicotine on probabilistic 
discounting. First, because nicotine treatment shifted behavior both toward (descending 
probabilities) and away from (ascending probabilities) choice of the large reward, 
nicotine did not likely alter choice behavior as a result of changes in reward detection or 
preference. The observed changes both toward and away from the large reward, even in 
the middle block of trails when rewards are equal on the two levers, also suggest that our 
results cannot be attributed to changes in preference for variable over fixed reward 
delivery.  
The findings observed in the probability discounting task following treatment 
with nicotine are similar to those seen following temporary inactivation of the PFC. In a 
recent study by St. Onge et al (2009), inactivation of mPFC resulted in an increase in 
preference for a large risky reward when testing with descending probabilities of reward 
delivery, while a decrease was observed when testing with ascending probabilities. 
These data replicate the findings of several studies showing that inactivation of PFC can 
promote perseverative behaviors (Baran et al. 2010; Del'Guidice et al. 2009). The 
authors of this study suggest these results may occur as a result of general disruptions in 
response flexibility represented as a failure to change responding in the face of changing 
reward values. Interestingly, a recently published study by St. Onge et al (2010) 
replicated the effect observed in probability discounting following inactivation of mPFC 
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using systemic administration of amphetamine. Because amphetamine is known to cause 
significant increases in dopamine levels within the corticomesolimbic system, these data 
suggests that increases in dopamine can also cause increases in response perseveration 
within the probabilistic discounting task. 
The effects observed in impulsive rats in the delay discounting task following 
treatment with nicotine, although not statistically significant, were in the direction of an 
increase in preference for the initially selected large reward. What remains unclear, 
however, is whether this increase in preference for this large delayed reward occurred as 
a result of improved cognitive performance or as a result of increased perseveration, as 
the large reward lever is the lever that was initially preferred. As mentioned above, only 
one other study has investigated the effects of nicotine in rats on performance in a delay 
discounting task (Dallery and Locey 2005). Contrary to our findings, in this experiment, 
animals treated with nicotine showed a decreased preference for the large delayed 
reward (increased impulsive choice) in a version of the delay discounting task that 
adjusts the delay to the large reward based on preference during the previous block of 
testing  (Mazur 1987). Interestingly, in this adjusted delay experimental design, choice 
preference for the large delayed reward during the first block was, on average, below 
50%. It is possible, then, that increases in choice of the small immediate reward 
following treatment with a high dose of nicotine in this version of the delay discounting 
task, as observed by Dallery and Locey (2005), were partially due to increases in 
perseverative responding for the reward option initially selected small, immediate 
reward lever. However, the design of the adjusted delay design used by Dallery and 
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Locey presents less of an opportunity for initial lever preferences than the set delay 
design used in Experiment 2, and therefore may be less susceptible to the development 
of response perseveration. Following this line of thought, if nicotine treatment does 
cause some degree of increased impulsive choice, in addition to the response 
perseveration inducing effects observed in Experiment 2.6, then this may explain why 
perseverative effects were not as prominent when testing in the delay discounting task in 
Experiment 2.2, than they were in the probability discounting task in Experiment 1.2. In 
other words, In Experiment 2.2, nicotine-induced increases in impulsive choice 
(decreased preference for the large delayed reward) may have washed out any extended 
responding for the initially selected larger reward, resulting from response perseveration. 
That is, any increases in impulsive choice (preference for the small immediate reward) 
caused by nicotine may not have been observable as a result of perseveration on the 
large reward lever. Indeed, the mechanisms underlying the increases in impulsive choice 
observed by Dallery and Locey following treatment with a low dose of nicotine remain 
unclear. 
Although it is reasonable to conclude that some type of perseverative behavior is 
occurring as a result of nicotine administration, this explanation cannot be generalized to 
all forms of cost-benefit decision making, as results from a recent experiment in our lab 
testing the effect of nicotine on a risk discounting task (in which the probability of a 
shock associated with a large reward increases across blocks), show no perseveration-
inducing effects of nicotine (Mitchell et al – in preparation). Additionally, research 
testing the effects of nicotine on reversal learning has produced mixed results; while 
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some studies have reported deficits in response flexibility following nicotine treatment, 
others have shown no effect (Brown et al. 2010; Loh et al. 1993).  
Future control studies, similar to those conducted in Experiment 2.6 for 
probability discounting, may help address the issue of perseverative responding in the 
delay discounting task following treatment with acute nicotine. If the delays used in 
Experiment 2 were presented in a descending order, with the large delay associated with 
the large reward in the first block, then we could expect that rats acutely treated with 
nicotine would initially prefer the small reward. Therefore, if the small increase in 
preference for the large delayed reward observed following nicotine treatment in 
Experiment 2.2 was due to an increase in perseverative responding, we would expect rats 
tested with descending delays to continue to choose the initially preferred small reward 
even as the delay to the large reward decreases; however, if increases in preference for 
the large reward following treatment with nicotine are due to decreases in impulsive 
choice then we would then expect nicotine treated rats to chose the large delayed reward 
more than saline controls, during the test session.  
It should be noted that increases in perseverative responding in the delay 
discounting task following acute nicotine treatment may also be linked to deficits in the 
temporal organization of behavior. Experiments examining the effects of nicotine on a 
version of the delay discounting task in which the delay to the large reward remains 
constant, may address the issue of nicotine-induced disruptions of long term monitoring 
of delays in the task. That is, changes in choice preference when testing the effects of 
nicotine in a version of the delay discounting task with constant delays, would suggest 
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that nicotine may impair the ability to appropriately guide behavior based on temporal 
information, rather than affect choice for rewards with different temporal costs. The 
pattern of results following nicotine administration is consistent with an interpretation of 
perseverative responding. However, the cause of this possibly perseverative behavior is 
not clear. One possibility is that increases in the salience of reward-related cues 
following treatment with nicotine results in increased preference for the initially selected 
reward. Acute treatment with nicotine has indeed been shown to increase preference for 
reward-related cues (Cohen et al. 2004; Olausson et al. 2004; Wang et al. 2007). The 
observed effects in the discounting tasks may therefore result from nicotine induced 
effects on attention and motivation for rewards and reward-related cues. That is, 
significant nicotine induced increases in the salience of rewards and reward-related cues, 
following treatment with nicotine, may account for nicotine-induced increases in 
motivation and preference for an initially more rewarding reward or reward-related cue, 
such that responding for those rewards and cues is maintained even when they become 
disadvantageous as the task progresses. Importantly, this initially selected reward may 
vary and will be dependent on the design of the given task. Research investigating the 
role of key structures within the mesolimbic system on cost-benefit decision making will 
be necessary to further characterize the role of nicotine in cost-benefit decision making.  
Results from Experiments 1 and 2 suggest that both nicotinic and muscarinic 
AChRs can affect cost-benefit decision making when delay of reward or risk of reward 
loss is involved. Experiment 3 used a different approach to further characterize a 
possible role of nAChRs in cost-benefit decision making, by examining correlations 
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between baseline levels of cost-benefit decision making and intrinsic nAChR subtype 
levels. This was accomplished by using receptor binding techniques in drug naive rats, to 
examine the relationship between intrinsic α4β2 and α7 nAChR subtypes levels and 
baseline performance on both the probabilistic and delay discounting task.  
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EXPERIMENT 3. RELATIONSHIP BETWEEN BASELINE NICOTINIC 
RECEPTOR LEVELS AND COST-BENEFIT DECISION MAKING 
 
The cholinergic system has been repeatedly shown to play a role in component 
processes involved in cost-benefit decision making, including executive function and 
reward motivation (Cutuli et al. 2008; Furey et al. 2008; Picciotto et al. 2008; Ricciardi 
et al. 2009; Zhang and Sulzer 2004). Recent findings from Experiment 2.6 further 
suggest that the cholinergic system is also involved in response flexibility, when testing 
cost-benefit decision making in the probability discounting task. As mentioned above, 
populations known to have deficits in cost-benefit decision making include patients with 
psychopathologies such as schizophrenia, Alzheimer’s disease, and addiction, among 
others (Clark and Robbins 2002; Coyle et al. 1983; Euteneuer et al. 2009; Kalivas and 
Volkow 2005; Thompson et al. 2007; Weiler et al. 2009; Yip et al. 2009). Patients with 
these conditions have characteristically impulsive and/or risky behaviors, which 
negatively impact many aspects of their lives (Clark and Robbins 2002; Coyle et al. 
1983; Euteneuer et al. 2009; Kalivas and Volkow 2005; Thompson et al. 2007; Weiler et 
al. 2009; Yip et al. 2009).  
Research using rodents with genetically “knocked-out” nAChR, as well as direct 
infusions of nicotinic agonists or antagonist into the prefrontal cortex and mesolimbic 
system of rodents, provides evidence for the involvement of nAChR in processes 
involved in cost-benefit decision making (Collins et al. 1989; George et al. 2000; Levin 
et al. 2009; Levin et al. 1997b; Marks et al. 1987; Reavill and Stolerman 1990). The 
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α4β2 and α7 nAChR subtypes in particular are highly expressed in the brain, and genetic 
deletion of these nAChR subtypes has been shown to cause behavioral impairments in 
tasks that measure component processes involved in cost-benefit decision making, such 
as conditioned place preference (preference for contexts associated with drug rewards) 
and 5 choice serial reaction task (attention for food reward associated stimuli) (Curzon et 
al. 2006; Hoyle et al. 2006; Walters et al. 2006). Similarly, direct infusions of nAChR 
agonists directly into the prefrontal cortex enhance cognitive processes implicated in 
cost-benefit decision making, such as working and reference memory for food rewards, 
while infusions of cholinergic antagonists in these structures impair these same functions 
(Levin et al. 2009; Levin et al. 1997b). These findings are complemented by human 
post-mortem studies and studies using radiolabeled ligand binding to identify AChR 
density levels in patients with schizophrenia and Alzheimer’s disease. Patients with 
these disorders show decreased levels of the α4β2 nAChR subtype in both the striatum 
and the cortex when compared to controls (Breese et al. 2000; Durany et al. 2000; Flynn 
and Mash 1986; Warpman and Nordberg 1995). Similarly, individuals diagnosed with 
schizophrenia have shown decreased levels of the α7 nAChR subtype within the 
prefrontal cortex (Guan et al. 1999).  
Receptor binding studies investigating cholinergic receptor levels in drug users 
have also identified changes in nAChR levels in structures implicated in cost-benefit 
decision making. Neuroimaging and post-mortem studies in nicotine addicts have 
reported increases in nAChR densities. Specifically, current smokers showed long-term 
increases in baseline α4β2 nAChR levels within the frontal cortex and striatum, when 
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compared to ex- and non-smoking controls (Breese et al. 1997; Court et al. 1998; 
Mukhin et al. 2008). Research with animals supports these findings, reporting increases 
in cortical and striatal autoradiographic binding of α4β2 nAChRs in rodents chronically 
exposed to nicotine (Collins et al. 1989; Marks et al. 1987). 
Only a handful of studies have used receptor binding techniques to investigate 
how baseline differences in nAChR may be related to baseline differences in cognitive 
function (Le Foll et al. 2009; Woodruff-Pak et al. 2008), and no studies to date have 
examined whether differences in baseline nAChR levels are related to differences in 
performance on tasks assessing cost-benefit decision making. To address relationships 
between nAChR expression and cost-benefit decision making, we used receptor 
autoradiography to correlate nAChR binding in brain areas implicated in cost-benefit 
decision making processes, with behavioral performance in the probability and delay 
discounting tasks. Results from these experiments were expected to speak to the 
possibility of using cholinergic α4β2 and α7 receptors as biomarkers and/or potential 
targets for the treatment of psychopathological conditions in which cost-benefit decision 
making is impaired. 
 
Experiment 3.1. Relationship Between α4β2 Nicotinic Receptors and Performance 
on the Probabilistic and Delay Discounting Tasks 
In the brain, the α4β2 nAChR subtype predominates in density and distribution 
and is implicated in executive and motivational processes (Granon et al. 2003; Le Foll et 
al. 2009; Perry et al. 2002; Picciotto et al. 1998; Woodruff-Pak et al. 2008). Receptor 
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binding studies have shown decreases in levels of α4β2 in prefrontal cortical areas of 
patients with schizophrenia and Alzheimer’s disease (Breese et al. 2000; Durany et al. 
2000; Flynn and Mash 1986; Warpman and Nordberg 1995). Additionally, receptor 
binding studies in nicotine dependent subjects have identified higher α4β2 nAChR 
density levels within the mesolimbic system (Breese et al. 1997; Court et al. 1998; 
Mukhin et al. 2008). These conditions have been associated with impaired cost-benefit 
decision making, including impulsive and risky behaviors (Clark and Robbins 2002; 
Coyle et al. 1983; Euteneuer et al. 2009; Kalivas and Volkow 2005; Thompson et al. 
2007; Weiler et al. 2009; Yip et al. 2009). Based on this research, along with the results 
observed in Experiment 1 and 2, we aimed to identify correlations between α4β2 nAChR 
subtype density levels and behavioral performance on the probability and delay 
discounting task.  
Results from Experiment 1.2 suggest that activation of nAChRs with a high dose 
of nicotine increases choice of the large risky reward in the probabilistic discounting 
task, while treatment with a low dose of nicotine decreases risky decision making in rats 
with high baseline levels of risky choice. Results from Experiment 2.6 further suggest 
that the effects observed in the probabilistic discounting task occurred as a result of 
increases in response perseveration, possibly due to enhanced motivational salience of 
the initially-selected reward. Because of the increase in response perseveration in the 
probabilistic discounting task following treatment with a high dose of nicotine, we 
predicted that higher levels of α4β2 nAChR levels would be associated with greater 
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preference for the large risky reward in the probability discounting task (increased risky 
choice).  
Based on the observed decrease in preference for the large risky reward 
following treatment with a low dose of nicotine, we further predicted that low levels of 
α4β2 nAChRs would be associated with decreased preference for the large risky reward 
(decreased risky choice), resulting in a positive linear relationship between choice of the 
large risky reward in the probability discounting task (risky choice) and α4β2 nAChR 
levels.  Perseverative, habitual responding may be occurring as a result of increases in 
dopaminergic firing within the mesolimbic system (Ellinwood and Kilbey 1975; Faure et 
al. 2010; Hsieh et al. 2010; Loh and Beck 1989). Based on this understanding, as well as 
research suggesting that nicotine induces dopamine release in the mesolimbic system 
(Mifsud et al. 1989; Rada et al. 2001; Wang et al. 2007), we predicted that increases in 
α4β2 nAChR levels correlated with increases in preference for the initially more 
rewarding choice (large reward lever), would be observed in structures within the 
mesolimbic system.  
Although results from Experiment 2.2 showed a significant main effect of 
nicotine administration in the impulsive subgroup of rats in the delay discounting task, 
no significant between group post-hoc effects were observed. Nonetheless, nicotine did 
appear to cause a slight increase in responding for the large reward, in impulsive rats. It 
remains unclear whether this increase was due to increases in response perseveration, 
improved cognitive performance, or some other effect of nicotine. Nonetheless, the 
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findings from both Experiments 1 and 2 suggest that increased activation of α4β2 
nAChRs may be associated with increased preference for the large delayed reward.  
Similar to our predicted results with probability discounting, we predicted a 
positive linear relationship between α4β2 nAChR levels and delay discounting, with 
increased preference for the large delayed reward (decreased impulsive choice) 
associated with higher levels of α4β2 nAChR. Whether the increases in preference for 
the large delayed reward in Experiment 2.2 occurred as a result of improved cognition or 
increased perseverative responding remains unclear. Because of this ambiguity, brain 
regions in which we would expect to see correlations between nAChR levels and 
decision making were difficult to predict; however, identified locations resulting from 
this research may help elucidate the mechanisms underlying increases in preference for 
the large, delayed reward following acute nicotine administration. For example, higher 
α4β2 nAChR levels within cortical regions associated with greater preference for the 
large delayed reward could suggest that the increase in preference for the large delayed 
reward following nicotine administration occurred as a result of improved cognitive 
function. Conversely, higher α4β2 nAChR density levels within mesolimbic system that 
are associated with greater preference for the larger delayed reward could suggest that 
the increase in preference for the large delayed reward occurred as a result of nicotine-
induced preservative responding. 
Treatment 
Rats were trained in both discounting tasks, as well as a number other behavioral 
tasks (instrumental responding on various schedules of reinforcement, open field test) 
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and sacrificed as described in the methods section above, and brains were sliced and 
prepared for receptor autoradiography. Heteromeric α4β2-containing nAChR were 
identified using 125I-epibatidine binding. For total binding, sections were incubated at 
room temperature with 0.4 nM [125I]-epibetadine for 1 hour, within the Tris-HCl buffer. 
Epibetadine-incubated slides were then exposed to the imaging film for 2 days to allow 
receptor level density analysis. 
Results  
Bi-variate correlations were observed between performance in the decision 
making tasks and other behavioral measures (Table 4). A positive linear correlation was 
observed between baseline performance in the two discounting tasks (r = .57, p < .05), 
such that as preference for the large risky reward increased, so did preference for the 
large delayed reward (Figure 12(A)). A positive linear correlation was also found 
between choice preference in the probability discounting task and performance in the 
Open Field Test (r = .50, p < .05), such that as choice preference for the larger risky 
reward increased, so did the total time the rat spent in the open, center region of the 
activity chamber (Figure 12(B)). Furthermore, there was a negative linear correlation 
observed between choice preference in the delay discounting task and performance in a 
fixed ratio 1 instrumental responding task (r = -.50, p < .05). In this correlation, 
preference for the larger delayed reward increased in the delay discounting task as the 
total number of lever presses decreased in the instrumental responding task (Figure 
12(C)).  
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Table 4. Correlation matrix displaying linear relationships between behavioral measures.  
 
 % 
choice 
of large 
risky 
reward 
% choice 
of large 
delayed 
reward 
Fixed 
Ratio 1
Fixed 
Ratio 3 
Fixed 
Ratio 10
Fixed 
Ratio 20
Fixed 
Ratio 40
Prog 
Ratio 
Horiz 
Activity 
Time in 
Center 
            
% choice 
of large 
risky 
reward 
 
X r = .57 p < .05* 
r = -.06 
p = .81 
r = -.31 
p = .25 
r = -.12 
p = .65 
r = -.35 
p = .19 
r = -.28 
p = .30 
r = -.21 
p = .44 
r = -.02 
p = .95 
r = .50 
p < .05*
% choice 
of large 
delayed 
reward 
 
X X r = -.50 p < .05*
r = -.39 
p = .14 
r = -.24 
p = .37 
r = -.27 
p = .31 
r = -.19 
p = .48 
r = .03 
p = .92 
r = -.11 
p = .70 
r = .04 
p = .89 
Fixed 
Ratio1 
 
X X X r = .35 p = .18 
r = .28 
p = .30 
r = .07 
p = .81 
r = .14 
p = .61 
r = -.21 
p = .43 
r = .35 
p = .19 
r = -.16 
p = .55 
Fixed 
Ratio 3 
 
X X X X r = .69 p < .01*
r = .56 
p < .05*
r = .53 
p < .05*
r = .02 
p = .95 
r = -.12 
p = .66 
r = -.12 
p = .65 
Fixed 
Ratio 10 
 
X X X X X r = .80 p < .01*
r = .85 
p < .01*
r = .41 
p = .11 
r = -.30 
p = .25 
r = .09 
p = .75 
Fixed 
Ratio 20 
 
X X X X X X r = .96 p < .01*
r = .73 
p < .01* 
r = -.30 
p = .26 
r = -.07 
p = .79 
Fixed 
Ratio 40 
 
X X X X X X X r = .73 p < .01* 
r = -.28 
p = .29 
r = -.14 
p = .68 
Prog 
Ratio 
 
X X X X X X X X r = -.20 p = .47 
r = -.23 
p = .38 
Horiz 
Activity 
 
X X X X X X X X X r = -.17 p = .53 
Time in 
Center 
 
X X X X X X X X X X 
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 (A)       (B) 
 
 
 
 
 
(C) 
 
 
 
 
 
 
 
 
 
 
 
Receptor density levels were assessed in cortical and limbic structures in the 
forebrain, as well as structures within the midbrain (Figure 13). Pearson’s bi-variate 
correlations were found between nAChRs in the brain and performance in both decision 
making tasks, as well as instrumental responding and open field behavioral measures. A 
Figure 12. Linear associations between behavioral measures. (A) Baseline performance in the 
probability discounting task was positively correlated with baseline performance in the delay 
discounting task, such that as preference for the large risky reward increased, so did 
preference for the large delayed reward. (B) Baseline performance in the probability 
discounting task was also positively correlated with baseline performance in the activity test, 
such that as preference for the risky delayed reward increased, so did time spent in the open 
center region of the activity chamber. (C) Baseline performance in the delay discounting task 
was negatively correlated with baseline performance in the fixed ratio 1 instrumental 
responding task, such that, as preference for the large delayed reward increased, total number 
of bar presses during a 30 minute FR1 instrumental responding test. * p < .05. 
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negative linear correlation was observed between performance in the probability 
discounting task and α4β2 nAChR density levels in the nucleus accumbens shell (r = -
.59, p < .05), such that as preference for the large risky reward increased, α4β2 nAChR 
density levels in the nucleus accumbens shell decreased (Figure 14).  
 
(A)      (B) 
 
 
 
 
 
 
(C)      (D) 
 
 
 
 
 
 
 
 
 
Figure 13. Cerebral structures in which nAChR subtype levels were determined. Twenty micrometer 
thick coronal brain sections were taken from (A) cortical (orbitofrontal OFC, medial prefrontal 
mPFC, infralimbic ILC, prelimbic PLC, cingulated CC, and agranular insular AIC cortex) and (B) & 
(C) limbic (nucleus accumbens shell NAcS and core NAcC, basolateral amygdala BLA, and dorsal 
hippocampus dHIPP) structures in the forebrain, as well as structures within the (D) midbrain 
(ventral tegmental area VTA). (Jones 2007) 
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Similar to results seen with the probability discounting task, a negative linear 
correlation was observed between performance in the delay discounting task and nAChR 
density levels in the nucleus accumbens shell (r = -.61, p < .05), in that greater 
preference for the large delayed reward was associated with lower α4β2 nAChR density 
levels in this region (Figure 15(A)). However, performance in the delay discounting task 
also had a similar correlation with α4β2 nAChR density levels in the dorsal 
hippocampus (r = -.60, p < .05), such that greater preference for the large delayed reward 
was associated with lower α4β2 nAChR density levels in this region (Figure 15(B)).  
Pearson’s bi-variate correlations were also used to investigate the relationships 
between baseline α4β2 nAChR density levels in specific brain regions and performance 
in several behavioral tasks (Table 5). A positive linear correlation was found between 
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Figure 14. Linear association between 
risky decision making and α4β2 nAChR 
density levels. Baseline performance in 
the probability discounting task was 
negatively correlated with baseline α4β2 
nAChR density levels. As preference for 
the large risky reward increased, α4β2 
nAChR density levels in the nucleus 
accumbens shell decreased. * p < .05. 
* 
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performance in the instrumental responding task on a fixed ratio 1 reinforcement 
schedule and nAChR levels in the orbitofrontal, medial prefrontal, and prelimbic cortex, 
as well as ventral and dorsal hippocampus (ps < .05), such that as responding in this 
version of the instrumental task increased, so did α4β2 nAChR density levels in these 
sites. Additionally, a similar relationship was found between performance in the 
progressive ratio version of the instrumental responding task and α4β2 nAChR density 
levels in the ventral hippocampus (p < .05). No correlations were observed between 
performance in the fixed ratio 3, 10, 20, and 40 versions of the instrumental responding 
task and α4β2 nAChR density levels in the brain regions assessed.  
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Figure 15. Linear association between impulsive decision making and α4β2 nAChR 
density levels. (A) Baseline performance in delay discounting task was negatively 
correlated with baseline α4β2 nAChR density levels. As preference for the large delayed 
reward increased, α4β2 nAChR density levels in the nucleus accumbens shell decreased. 
(B) Baseline performance in delay discounting task was also negatively correlated with 
baseline α4β2 nAChR density levels. As preference for the large delayed reward 
increased, α4β2 nAChR density levels in the hippocampus also decreased.  
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Table 5. Correlation matrix displaying linear relationships between α4β2 nAChR density 
levels and performance in behavioral tasks. 
 
% choice of 
large risky 
reward 
% choice of 
large delayed 
reward 
Fixed Ratio1 Progressive Ratio 
Horizontal 
Activity 
OFC r = -.22 p = .44 
r = -.35 
p = .20 
r = .59 
 p < .05* 
r = -.40 
p = .14 
r = .62 
 p < .05* 
mPFC r = -.31 p = .26 
r = -.27 
p = .33 
r = .57 
 p < .05* 
r = -.14 
p = .63 
r = .63 
 p < .05* 
CC r = .22 p = .41 
r = .19 
p = .49 
r = .16 
p = .56 
r = -.39 
p = .13 
r = .43 
    p = .09 
PLC r = -.26 p = .34 
r = -.30 
p = .28 
r = .56 
 p < .05* 
r = -.26 
p = .35 
r = .36 
p = .19 
ILC r = -.18 p = .54 
r = -.37 
p = .19 
r = .44 
p = .11 
r = -.14 
p = .64 
r = .06 
p = .83 
AIC r = .09 p = .75 
r = .03 
p = .91 
r = .07 
p = .80 
r = -.43 
p = .10 
r = .15 
p = .58 
vHipp r = -.03 p = .92 
r = -.25 
p = .36 
r = .57 
 p < .05* 
r = -.54 
 p < .05* 
r = .44 
p = .09 
dHipp r = -.03 p = .91 
r = -.60 
 p < .05* 
r = .53 
 p < .05* 
r = -.40 
p = .13 
r = .23 
p = .39 
NAcC r = .21 p = .45 
r = .10 
p = .73 
r = .44 
p = .11 
r = -.36 
p = .18 
r = .65 
 p < .01* 
NAcS r = -.59  p < .05* 
r = -.61 
 p < .05* 
r = .37 
p = .19 
r = -.03 
p = .92 
r = .59 
 p < .05* 
BLA r = -.10 p = .75 
r = -.54 
p = .07 
r = .10 
p = .76 
r = -.35 
p = .27 
r = .07 
p = .83 
VTA r = .21 p = .45 
r = -.08 
p = .78 
r = -.05 
p = .85 
r = -.50 
p = .06 
r = -.15 
p = .59 
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Density levels of α4β2 nAChRs were also linearly correlated with horizontal 
activity in the Open Field Test, such that as horizontal photobeam breaks increased, so 
did α4β2 nAChR density levels in the orbitofrontal and medial prefrontal cortex (ps < 
.05). Additionally, a similar positive correlation was found between horizontal 
photobeam breaks and α4β2 nAChR density levels in the nucleus accumbens  
core and shell (ps < .05). No correlations were found between time spent in the center 
region of the activity chamber and α4β2 nAChR density levels in the brain. 
Several correlations were observed between α4β2 receptor binding in specific 
brain regions and performance on the decision making tasks. In particular, a negative 
linear correlation was observed between α4β2 nAChR levels in the nucleus accumbens 
shell and preference for the large risky reward in the probability discounting task, such 
that as α4β2 nAChR levels in the nucleus accumbens shell increased, preference for the 
large risky reward decreased (decreased risky choice). These findings do not support our 
predicted results (based on our behavioral pharmacological experiments) that higher 
levels of α4β2 nAChR would be associated with greater preference for the large risky 
reward (increased risky choice). A negative linear correlation was also observed between 
the delay discounting task and α4β2 nAChR levels in the nucleus accumbens shell and 
dorsal hippocampus. As α4β2 nAChR density levels in the nucleus accumbens shell and 
dorsal hippocampus increased, preference for the large delayed reward decreased 
(increased impulsive choice). These finding do not support our predicted results (based 
on our behavioral pharmacological experiments) that higher levels of α4β2 nAChR 
would be associated with greater preference for the large delayed reward (decreased 
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impulsive choice). Although the role of α4β2 nAChR in cost benefit decision making 
remains unclear, the findings from this experiment do suggest that α4β2 nAChR are 
indeed involved in cost-benefit decision making. Furthermore, the negative correlation 
between high levels of α4β2 nAChR with greater preference for the large reward in both 
tasks suggests shared neurobiological mechanisms. 
  
Experiment 3.2. Relationship Between α7 Nicotinic Receptors and Performance on 
the Probabilistic and Delay Discounting Tasks 
As mentioned above, these experiments focused on nAChR subtypes with roles 
well established in executive function and reward motivation. The α7 nAChR subtype 
comprises about 10% of all nAChRs in the mammalian brain and is also implicated in 
executive function and incentive motivation (Curzon et al. 2006; Hoyle et al. 2006; 
Keller et al. 2005; Young et al. 2004; Zanetti et al. 2006); however, research on the role 
of the α7 nAChR subtype in executive function and incentive motivation is more limited 
than that on α4β2 (Berger et al. 1998; Chang and Berg 1999; Gray et al. 1996; Hefft et 
al. 1999; McGehee et al. 1995; Messi et al. 1997). Of note, receptor binding studies have 
shown decreases in α7 nAChR levels in prefrontal cortical areas of patients with 
schizophrenia and Alzheimer’s disease (Breese et al. 2000; Durany et al. 2000; Flynn 
and Mash 1986; Warpman and Nordberg 1995).  
As discussed in Experiment 3.1, results from our behavioral pharmacological 
experiments (Experiment 1.2 and 2.2) suggest that activation of nAChRs following 
treatment with a high dose of nicotine can increase choice of the large risky or delayed 
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reward in the probabilistic or delay discounting tasks, respectively. Therefore, we 
predicted that higher levels of α7 nAChR levels would be associated with greater 
preference for the large risky reward in the probability discounting task (increased risky 
choice) and the large delayed reward in the delay discounting task (decreased impulsive 
choice). As discussed,  the perseverative, habitual responding observed in the 
probabilistic discounting task may be occurring as a result of increases in dopaminergic 
firing within the mesolimbic system (Ellinwood and Kilbey 1975; Faure et al. 2010; 
Hsieh et al. 2010; Loh and Beck 1989). Based on this understanding, as well as research 
suggesting nicotine-dependent increases in dopamine  levels (Mifsud et al. 1989; Rada et 
al. 2001; Wang et al. 2007), we predicted that the relationship between probabilistic 
discounting and nAChR density levels would be linear and that increases in nAChR 
levels would be seen in structures found within the mesolimbic system. Whether the 
increases in preference for the large delayed reward in the delay discounting task 
occurred as a result of improved cognition or increased perseverative responding 
remains unclear; therefore, areas in which nAChR levels may be correlated with this task 
are difficult to determine. Identified locations resulting from this research may help 
elucidate the mechanisms underlying our observed increase in preference for the large, 
delayed or risky reward following acute nicotine administration.  
Treatment 
Using receptor autoradiography, homomeric α7 nAChRs were identified using 
125I-labeled α-bungarotoxin. For total binding, sections were incubated at room 
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temperature with 5 nM [125I]-α-bungarotoxin for 2 hours, within the Tris-HCl buffer. 
Film was exposure to α-bungarotoxin slides for 3 days.  
Results  
Pearson’s bi-variate correlations were used to investigate the relationships 
between baseline α7 nAChR density levels in specific brain regions and baseline 
performance in several behavioral tasks (Table 6). A negative linear correlation was 
observed between performance in the delay discounting task and nAChR density levels 
in the basolateral amygdala (r = -.54, p < .05), in that greater preference for the large 
delayed reward was associated with lower α7 nAChR density levels in this region 
(Figure 16). Performance in the probability discounting task was not associated with α7 
nAChR density levels in any brain regions analyzed.  
Similar to results seen with α4β2 nAChR, a positive linear correlation was found 
between performance in the instrumental responding task with a fixed ratio 1 
reinforcement schedule and α7 nAChR levels in several areas within the brain, including 
the orbitofrontal and agranular insular cortex, as well as the nucleus accumbens core and 
basolateral amygdala (ps < .05), such that as responding in this version of the 
instrumental task increased, so did α7 nAChR density levels in these sites. No linear 
correlations were observed between performance in the fixed ratio 3, 10, 20, and 40 
versions of the instrumental responding task and α7 nAChR density levels in the brain 
regions that were assessed. Additionally, a negative linear relationship was found 
between performance in the progressive ratio version of the instrumental responding task 
and α7 nAChR density levels in  the orbitofrontal and agranular insular cortex (p < .05).  
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Table 6. Correlation matrix displaying linear relationships between α7 nAChR density 
levels and performance in behavioral tasks. 
 
% choice of 
large risky 
reward 
% choice of 
large delayed 
reward 
Fixed Ratio1 Progressive Ratio 
Horizontal 
Activity 
OFC r = .37 p = .18 
r = -.38 
p = .16 
r = .62 
 p < .05 * 
r = -.61 
 p < .05 * 
r = .08 
p = .77  
mPFC r = .18 p = .50 
r = -.36 
p = .19 
r = .30 
p = .28  
r = -.22 
p = .43 
r = -.11 
p = .69 
CC r = .25 p = .37 
r = .11 
p = .69 
r = .02 
p = .96 
r = -.27 
p = .34 
r = -.19 
     p = .51 
PLC r = .14 p = .62 
r = -.40 
p = .14 
r = .42 
p = .12  
r = -.23 
p 
r = -.04 
p = .88 
ILC r = .02 p = .93 
r = .42 
p = .12 
r = .24 
p = .39 
r = -.06 
p = .84 
r = -.17 
p = .54 
AIC r = .26 p = .35 
r = .25 
p = .37 
r = .54 
 p < .05 * 
r = -.54 
 p < .05 * 
r = .15 
p = .60 
vHipp R = -.06 p = .82 
r = -.03 
p = .90 
r = .11 
p = .68  
r = .18 
p = .50  
r = -.14 
p = .61 
dHipp R = -.06 p = .83 
r = -.22 
p = .42 
r = .33 
p = .21  
r = -.11 
p = .68 
r = .31 
p = .24 
NAcC r = .16 p = .67 
r = .31 
p = .39 
r = .64 
 p < .05 * 
r = .29 
p = .41 
r = .28 
p = .44 
NAcS R = -.32 p = .25  
r = -.28 
p = .31  
r = .11 
p = .71 
r = -.04 
p = .90 
r = -.04 
p = .88  
BLA R = -.41 p = .13 
r = -.54 
 p < .05 * 
r = .53 
 p < .05 * 
r = -.27 
p = .33 
r = .61 
 p < .05 * 
VTA R = -.12 p = .68 
r = -.05 
p = .85 
r = -.15 
p = .59 
r = .05 
p = .85 
r = -.26 
p = .35 
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Density levels of α7 nAChRs were also positively correlated with horizontal activity in 
the Open Field Test, such that as horizontal photobeam breaks increased, so did α7 
nAChR density levels in the basolateral amygdala (ps < .05). No correlations were found 
between time spent in the open center region of the activity chamber and α7 nAChR 
density levels in the brain. 
 
 
 
 
 
 
 
 
 
 
 
Results suggest that α7 nAChR density levels are not associated with choice 
preference in the probability discounting task. In the delay discounting task, results show 
that as α7 nAChR density levels in the basolateral amygdala increased, choice of the 
large delayed reward decreased (increased impulsive choice), resulting in a negative 
linear relationship. Similar to Experiment 3.1, findings from the delay discounting task 
did not support our prediction (based on our behavioral pharmacological experiments) 
Figure 16. Linear association between impulsive 
decision making and α7 nAChR density levels. 
Baseline performance in the delay discounting task 
was negatively correlated with baseline α7 nAChR 
density levels. As preference for the large delayed 
reward increased, α7 nAChR density levels in the 
basolateral amygdala decreased. * p < .05.
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that higher levels of α7 nAChR levels would be associated with greater preference for 
the large delayed reward (decreased impulsive choice). Although the role of α7 nAChR 
in cost benefit decision making remains unclear, the findings from this experiment 
suggest that α7 nAChR are indeed involved in cost-benefit decision making.  
 
Experiment 3 Summary and Discussion 
In Experiment 3, the relationships between performances in several behavioral 
tasks were assessed. Among the various behavioral measures there were several 
significant linear correlations; of particular interest, however, was a positive linear 
correlation between the probability and delay discounting tasks, showing that greater 
preference for the large risky reward was associated with greater preference for the large 
delayed reward. Correlations observed between probability and delay discounting may 
suggest similar underlying cognitive and neuronal processes involved in action-outcome 
contingencies (Green and Myerson 1996; Mazur 1997; Sozou 1998).  
This finding is not entirely surprising since it has been suggested by some studies 
that probability and delay discounting may share similar underlying processes (Green 
and Myerson 1996; Mazur 1997; Sozou 1998). For example, choosing an uncertain 
reward for 5 trials, and receiving it only after the 5th trial can be somewhat equivalent to 
a very long delay (Cardinal 2006). In addition, the reward type is identical and the 
reward magnitudes are very similar in both discounting tasks, resulting in some likely 
contextual overlap between the two tasks. Nonetheless, dissociable processes, such as 
differences in eventual predictability of rewards and absolute reward magnitude, may be 
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observed between discounting of delayed rewards and discounting of uncertain rewards 
(Green and Myerson 2004; Ho et al. 1999; Mitchell 2003; Simon et al. 2009), and 
several previous studies from our laboratory have shown no relationship between 
performance in the two tasks (Mendez et al. 2010; Simon et al. 2009). More research is 
needed to identify shared and separate target mechanisms for the treatment of impaired 
risky and impulsive behaviors. 
A correlation was also found between performance in the probabilistic 
discounting task and locomotor activity in the Open Field Test, such that animals that 
were more likely to choose the large risky reward were also more likely to spend more 
time in the open center region of the activity chamber. The association between 
increases in choice of the large risky reward and time spent in the center of the chamber 
during the activity test is not surprising, as time spent in a open field has often been used 
as a measure of anxiety and risky behavior (Mikics et al. 2005). Finally, a correlation 
was found between the delay discounting task and instrumental responding for food 
reward, such that greater preference for the large delayed reward was associated with 
less total lever pressing during a 30 minute test session in the fixed ratio 1 version of the 
instrumental responding task. This relationship is consistent with the hypothesis that 
increased responding on low fixed reinforcement schedules reflects greater sensitivity to 
immediate reinforcement (Johansen et al. 2009; Sagvolden et al. 1992a; Sagvolden et al. 
1992b). 
Results from Experiments 1 and 2 suggest that pharmacological manipulation of 
both nicotinic and muscarinic AChRs can affect cost-benefit decision making when 
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delay of reward or risk of reward loss is involved. ACh levels within the nucleus 
accumbens, hippocampus, and amygdala have all been associated with changes in 
processes implicated in cost benefit decision making, such as motivation for reward 
seeking and taking, and processes involved in the learning and memory concerning 
reward and reward associated cues (Crespo et al. 2006; Schroeder and Packard 2004; 
Smith et al. 2004a; Smith et al. 2004b). Results from Experiment 3 associate differences 
in nAChR levels within all of these structures with differences in cost-benefit decision 
making. Data from Experiment 3.1 suggest that higher α4β2 nAChR levels in the 
nucleus accumbens shell are associated with decreased preference for the large risky 
reward in the probability discounting task (decreased risky decision making) and 
decreased preference for the large delayed reward in the delay discounting task 
(increased impulsive decision making). Furthermore, it was found that increases in α4β2 
nAChR levels in the dorsal hippocampus were associated with decreased preference for 
the larger delayed reward in the delay discounting task.  
Although some of the specific brain areas in which we observed relationships 
between nAChR levels and performance in the discounting tasks were unexpected, 
research has been conducted that may elucidate why these areas may be implicated. The 
association between lower levels of α4β2 nAChR levels in the ventral hippocampus and 
higher breakpoints when responding for food on the progressive ratio task is similar to 
that seen in a recent study that implicates the hippocampus in addictive behaviors. Using 
squirrel monkeys, Le Foll et al (2009) found that lower levels of α4β2 nAChR within the 
hippocampus were associated with higher breakpoints when responding for intravenous 
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nicotine on a progressive ratio schedule. These findings may help explain the observed 
association found between α4β2 nAChR levels in the dorsal hippocampus and choice 
preference in the delay discounting task. That is, because rats with lower levels of α4β2 
nAChR within the hippocampus were more likely to work and wait for a future reward 
in the progressive ratio task (represented by higher breakpoints), then it may also be 
expected that rats with lower levels of α4β2 nAChRs within the hippocampus would also 
be more likely to wait for larger, albeit delayed, reward in the delay discounting task.  
Results from Experiment 3.2 show that although α7 nAChR density levels are 
not associated with choice preference in the probability discounting task, α7 receptor 
levels are associated with choice preference in the delay discounting task. Activation of 
α7 nAChRs on the terminals of dopaminergic neurons projecting from the VTA to the 
ventral striatum is implicated in dopamine release within the nucleus accumbens; 
however, no significant correlations between α7 levels in nucleus accumbens and 
impulsive or risky decision making were observed. Interestingly, increases in α7 nAChR 
density levels in the basolateral amygdala were (BLA) were associated with decreased 
preference for the large delayed reward (increased impulsive choice). Destruction of the 
BLA has been shown to increase impulsive choice (Winstanely Theobald, Cardinal, 
Robbins 2004), an effect that may result from impairments in utilizing representations of 
the incentive value of delayed rewards to guide behavior. Therefore, high levels of α7 
nAChR levels within the BLA may be causing effects similar to those observed with 
BLA inactivation – i.e. causing the value of large reward to not be maintained across 
delays, and in turn promoting impulsive choice. Finally, the fact that there were fewer 
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associations between α7 nAChR and performance in cost-benefit decision making tasks 
relative to α4β2 nAChR may reflect the relatively lower levels of expression of α7 
nAChRs in the brain.  
Activation of nAChR in the nucleus accumbens has been shown to induce 
increases in processes that promote responding for large rewards, including attention to, 
learning of, and/or motivation for, rewards and reward-related cues  (Mifsud et al. 1989; 
Rada et al. 2001; Wang et al. 2007). Therefore, the observed associations between 
increases in α4β2 nAChR level in the nucleus accumbens shell and decreases in 
preference for the large reward in both the delay and probability discounting task in 
Experiment 3.1 were a bit surprising. One explanation for this discrepancy may lie in the 
fundamental difference between the effects of nAChR activation resulting from 
endogenous receptor activation (such as that occurring in our untreated rats in 
Experiment 3) and receptor activation resulting from exogenous drug administration 
(such as that occurring in our nicotine-treated rats in Experiments 1 and 2). While higher 
levels of endogenous nAChR activation may lead to decreased preference for a larger 
reward, activation of nAChR with a high dose of nicotine may cause greater preference 
for larger rewards.  
One explanation for the observed relationship between higher levels of 
endogenous nAChRs and lower preference for large rewards may stem from a recent 
study in which the authors propose that ACh within the nucleus accumbens shell is 
involved in avoidance behaviors, possibly through mediation of GABAergic output 
(Hoebel 2007). In this study, microdialysis during several avoidance behaviors shows 
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that increases in aversive behavior correlate with increases in acetylcholine release in the 
shell (such as that which occurs at the end of a meal). These findings suggest that 
endogenous acetylcholine activation of nAChRs within the shell may be causing 
increases in avoidance (of delays to reward or risk of loss of reward) in rats with higher 
levels of α4β2 nAChR in the nucleus accumbens shell. 
The effects of systemic injections of nicotine in Experiment 1 and 2 were most 
prominent in the probability discounting task in rats that had low choice preference for 
the large risky reward, and were limited in the delay discounting task to rats that had low 
choice preference for the large delayed rewards. When further considering the results of 
Experiment 3, as well as research showing that activation of nAChR in the nucleus 
accumbens are involved in processes that promote responding for large rewards, 
including attention to, learning of, and/or motivation for, rewards and reward-related 
cues  (Mifsud et al. 1989; Olausson et al. 2006; Rada et al. 2001; Wang et al. 2007), it 
may be argued that rats with low baseline preference for the large risky or delayed 
rewards in Experiments 1 and 2 were also the rats that had the highest baseline levels of 
nicotinic receptors within the nucleus accumbens shell. Therefore, it is possible that in 
Experiments 1 and 2, any observed increases in preference for the large risky or delayed 
reward occurred in rats with low baseline preference for this reward because they had a 
higher number of available nAChR onto which systemically injected nicotine could 
bind, and subsequently exert a large effect (increased motivation for rewards and reward 
related cues).  
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As suggested in Experiment 2, increases in perseverative responding following 
systemic injections of nicotine may be due to increases in attention and motivation 
directed toward an initially presented larger reward, to the degree that appropriate 
consideration of subsequent changes in reward-cost contingencies are impaired. Given 
that AChR have been highly implicated in behavioral and biological component 
processes involved in cost-benefit decision making, the lack of associations between 
nAChR subtypes levels in cortical structures implicated in cost-benefit decision making 
and performance in the discounting tasks was surprising. Interestingly, however, it has 
been repeatedly shown that several processes relevant to cost benefit decision making 
(learning, motivation) can be affected by cholinergic and dopaminergic interactions 
(Bertorelli and Consolo 1990; Imperato et al. 1994; Puttfarcken et al. 2000; Weiner et al. 
1990; Zanetti et al. 2006). This suggests that nAChR activation may not directly affect 
cortical-dependent processes involved in cost-benefit decision making, including 
decision making and conflict resolution, but instead may act indirectly through other 
neurotransmitter systems.  
Research suggests that the effects of cholinergic and dopaminergic interactions 
within the mesolimbic system on cost-benefit decision making may be modulated by the 
feed-forward, complementary organization of cholinergic and dopaminergic neurons 
(Balfour 2004; David et al. 2006; Mifsud et al. 1989; Rada et al. 2001; Wang et al. 
2007). It may therefore be the case that nicotine’s effects on cost-benefit decision 
making are indirect and mediated by nAChR-dependent increases in dopamine release. 
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More research is needed to examine how cholinergic interactions with other 
neurotransmitters (particularly dopamine) can affect cost-benefit decision making. 
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SUMMARY, DISCUSSION, AND CONCLUSIONS 
 
Results Summary 
Current research suggests a role for both nicotinic and muscarinic AChRs in 
psychological processes necessary for cost-benefit decision making, including executive 
functions involving the PFC and incentive motivation involving the mesolimbic system 
(Cutuli et al. 2008; Furey et al. 2008; Picciotto et al. 2008; Ricciardi et al. 2009). To 
date, however, there has only been one study that has used animals to investigate the 
causal role of cholinergic systems in cost-benefit decision making (Dallery and Locey 
2005). The present study suggests that the cholinergic system is indeed involved in cost-
benefit decision making. Specifically, results suggest that increases in acetylcholine 
levels resulting from inhibition of acetylcholinesterase decrease risky behavior in risk-
taking rats (Experiment 1.1). Results also suggest that activation of nAChRs by nicotine 
increases risky decision making (Experiment 1.2), whereas blockade of nAChRs causes 
a decrease in risky decision making (Experiment 1.4). Investigation of the role of 
mAChRs in probabilistic discounting was limited due to an increase in response 
omissions. Limited data, however, do show that activation of mAChRs does not appear 
to affect risky decision making (Experiment 1.3), while blockade of mAChRs can cause 
poor decision making across the probability discounting task (Experiment 1.5). 
Regarding the role of cholinergic receptors in impulsive decision making, results suggest 
that inhibition of acetylcholinesterase does not appear to affect impulsive choice 
(Experiment 2.1). Results from this task do suggest, however, that activation of nAChRs 
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decreases impulsive choice in impulsive rats (Experiment 2.2). Blockade of nAChRs 
also affected impulsive choice in impulsive rats, although the directionality of these 
effects was difficult to interpret (Experiments 2.4). Blockade of mAChR appeared to 
decrease impulsive choice in both impulsive and non-impulsive rats (Experiment 2.5), 
while activation of these receptors with oxotremorine caused effects that appeared to 
depend on baseline levels of impulsive choice (Experiment 2.3). Finally, analysis of 
radioligand binding densities for specified nAChR subtypes suggests that α4β2 and α7 
nAChR may be related to risky and/or impulsive choice as determined by the 
probabilistic and delay discounting task, and that nAChR in selected subcortical 
structures (NAcc, Hipp, BLA) may be directly involved in cost-benefit decision making 
(Experiment 3). 
 
General Discussion and Conclusions 
The overall goal of this dissertation was to determine the role that cholinergic 
receptors play in cost-benefit decision making. Results from Experiment 1 identify a 
number of effects on performance in the probability discounting task following 
cholinergic manipulations; however, the most prominent effect observed was a nicotine-
induced increases in risky decision making. The results from control studies suggest that 
these effects may be due, at least in part, to increases in perseverative responding. In 
Experiment 2, several effects on performance in the delay discounting task were 
observed following cholinergic receptor manipulation, with the most prominent effect 
observed being an increase in impulsive decision making following treatment with the 
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mAChR antagonist atropine. These findings suggest that cholinergic receptors are indeed 
involved in cost-benefit decision making and that the mechanisms underlying different 
types of cost-benefit decision making (impulsive, risky) are dissociable.  
Results from this dissertation also suggest that intrinsic differences in nAChR 
subtype levels within mesolimbic structures (NAcc, Hipp, BLA) can predict baseline 
levels of impulsive and risky decision making. Negative correlations were observed 
between nAChR subtype levels in the nucleus accumbens shell and preference for the 
large delayed or risky reward, suggesting that shared mechanisms may underlie the 
observed increase in preference for the large reward in the two discounting tasks. 
Contrary to what was expected based on Experiment 1 and 2 (in which increases in 
activation of nAChR was associated with greater preference for the large risky or 
delayed reward), findings from Experiment 3 showed that increases in nAChR levels 
predict decreased preference for the large risky or delayed reward. However, when 
considering that the most prominent effects of nicotine were seen in rats with low 
baseline preference for the large reward regardless of risk (animals presumed to have 
high baseline levels of nAChR), one may conclude that high baseline levels of nAChR 
serve to predispose animals to larger increases in preference for large rewards following 
high levels of exogenous nAChR activation (perhaps as a result of the overall greater 
number of nAChRs that can respond to the agonist).  
Given the feed-forward organization of ACh and dopamine interactions within 
the mesolimbic system, and the role of dopamine in encoding rewards and reward-
related cues, one would predict that increases in cholinergic receptor activation would 
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increase attention towards and motivation for reward associated stimuli. Similar effects 
are indeed observed following treatment with the dopamine increasing drug 
amphetamine (St Onge et al. 2010). These shared effects may be due to their shared 
neurobiological functions and feed-forward organization. Similarly, the apparent 
increase in preference for the larger delayed reward when testing the effects of nicotine 
in the delay discounting task (albeit small, and limited to the impulsive subgroup of rats) 
are similar to those reported in a recent study in which acute amphetamine increased 
preference for the large delayed reward in the delay discounting task (Setlow et al. 
2009). Again, these findings support the idea that acetylcholine and dopamine work in a 
feed-forward manner that can amplify attention and motivation for rewards and reward 
related cues. 
Notably, no correlations between nAChR subtypes in structures within the PFC 
and choice preference in the delay or probability discounting task were observed. 
Correlations between mAChR subtypes within these key structures on cost-benefit 
decision making are unknown. Therefore, although the PFC is strongly implicated in 
cost-benefit decision making, the role of ACh within the PFC may be limited to 
activation of mAChRs. Future research should continue to identify nicotinic and 
muscarinic cholinergic mechanisms involved in cost-benefit decision making.  Such 
studies could expand our findings by examining the effects of administration of 
cholinergic drugs that bind to specific nicotinic and muscarinic receptor subtypes on 
performance in cost-benefit decision making tasks. These proposed studies could be 
even more informative if administration of these drugs were limited to the specific brain 
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regions that Experiment 3 identified as being associated with individual differences in 
cost-benefit decision making (NAcc, Hipp, BLA). Finally, this research could be even 
more particularly useful when conducted with animals that model psychopathological 
conditions in which there is known to be impaired cost-benefit decision making. This 
dissertation project offers, for the first time, insight into the role of acetylcholine in risky 
and impulsive decision making, possibly providing data for the advancement of, 
intervention and care for individuals suffering from impaired cost-benefit decision 
making. 
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